Listen to this article Listen to this article

John Agos

Bennabis Health

A 35-year veteran executive in the health care, nonprofit associations and pharmaceuticals spaces, Agos is CEO and board member of Bennabis Health, a Cranford-based startup focused on making medical cannabis more affordable and accessible for patients. He has been instrumental in leading the company. Using science-based education and expertise, Agos and his team have worked to build benefit programs for effective medicinal cannabis use, providing support for employer groups and individual patients who join Bennabis Health’s program.

Agos has been driving innovation in health care by normalizing medical cannabis, and under his leadership, Bennabis Health has achieved multiple milestones, including implementing the nation’s first employer benefit for medical cannabis at such New Jersey organizations as the City of Trenton, and the Orange and Teaneck boards of education.

Agos also steered Bennabis Health’s innovative partnership with Broadreach Medical Resources, a pharmacy benefit manager located in New York City. Under the first-ever arrangement with BMR and Bennabis Health, medical cannabis is seamlessly integrated into traditional employee health coverage, helping covered employees to manage medical conditions while reducing health plan costs.

Kevin Ali

Organon

Ali leads Organon, a global company focused on investing in treatments for conditions that affect women uniquely, disproportionately or differently. Ali brings to Organon – formed from a spinoff from Merck in 2021 – more than 30 years of health care and commercial experience.

Organon’s diverse portfolio offers solutions across a range of areas including reproductive health, cardiovascular disease, neurology, autoimmune and respiratory conditions. At Organon, Ali works to build an ecosystem of like-minded partners and innovators to advance women’s health care through innovation, access and choice. Notable achievements in 2024 include the expansion of Organon’s commercialization agreement with Eli Lilly for Emgality, which enhances the company’s global product portfolio for conditions that disproportionately impact women, such as migraines. With the acquisition of Dermavant – Organon’s largest deal since spin – the company added to its portfolio VTAMA, the only non-steroidal topical approved for mild, moderate and severe atopic dermatitis. The acquisition provides access to all segments of the market in patients as young as 2 years of age.

Additionally, the company’s flagship contraception product, Nexplanon, is well positioned to deliver $1 billion in revenue in 2025; while Jada, the company’s device for post-partum hemorrhage, celebrated 100,000 units shipped since launch.

Jim Andrews

Deborah Heart and Lung Center

An established health care leader, Andrews was appointed as president and CEO of Deborah Heart and Lung Center in September 2024, with the goal of creating the first people-centered care model for heart and lung patients in the country. He is already leading new organizational advancements, which include strategic investments in capital projects, launching new clinical programs, adding pivotal team members and finalizing the opening a new $108 million patient tower.

He is also heading the hospital’s response to increased competition by using Deborah’s unique mission and ability to outperform the market in quality, patient satisfaction and price transparency as the cornerstones for future success.

As New Jersey continues to see the advancement of larger and larger health systems, Andrews is working to fortify the institution’s ability to remain independent, with a focus on concierge-level care for patients and their families. He is positioning the hospital for growth in 2025 and beyond with a three-part strategic reinvestment initiative aimed at increasing awareness about Deborah’s expertise, introducing tailored training to enhance employees’ skills and improving processes, and expanding capabilities to meet evolving needs of patients.

Cathleen Bennett

New Jersey Hospital Association

A former state health commissioner, Bennett has served as president and CEO of the New Jersey Hospital Association since 2017. With a mission to improve the health of the people of New Jersey, NJHA fulfills a vital role, with functions that include quality improvement and patient safety, data modeling and analysis, policy and advocacy, education, emergency preparedness and more.

As part of a drive to expand NJHA’s capabilities, Bennett has elevated the organization’s technology, bringing its already-impressive data analysis capabilities to an even higher level, which was evident during the pandemic and through its research from the Center for Health Analytics, Research and Transformation. Under Bennett, NJHA also established a workforce data center that enables deeper connections with core providers, government and other partners as they craft solutions for common issues like the health care workforce shortage, recruitment, development and retention.

During her tenure, NJHA has led initiatives on mental health, maternal health, veterans’ health and others. In 2025 and beyond, Bennett will continue to advocate for health care enhancements at local, state, federal and other levels.

Dr. Robert Brenner

Valley Health System

In July 2024, Brenner was promoted to president and CEO of Valley Health System. In this role, he has overseen the operations of the system’s three entities: The Valley Hospital, Valley Home Care and Valley Medical Group. The Valley Hospital has been recognized with the Healthgrades America’s 100 Best Hospital Award for three years in a row (2023-2025) and is one of only four hospitals in New Jersey — and the only one in Bergen County — to receive the award.

During his tenure at Valley, Brenner has played a significant role in the growth of Valley’s award-winning medical group, home care and the planning of The Valley Hospital’s move to Paramus in April 2024. He also led, in affiliation with the Icahn School of Medicine at Mount Sinai, the initiation of Valley’s first two Graduate Medical Education programs in Internal Medicine and Obstetrics and Gynecology in July 2024.

Looking ahead, Brenner plans to continue to expand Valley’s footprint through the introduction of even more medical programs and services; transform the Valley Health System – Ridgewood Campus through the addition of new ambulatory care services; and expanding graduate medical education with the introduction of a surgical residency program, which will matriculate the first class of residents in the summer of 2025.

Chrissy Buteas

HealthCare Institute of New Jersey

As president and CEO at the HealthCare Institute of New Jersey, Buteas leads a dynamic organization that represents New Jersey’s biopharmaceutical and medical technology community. Her vision for the organization and the industry is to maintain New Jersey’s historic reputation as “the Medicine Chest of the World,” by promoting sound public policies at both the federal and state levels to enhance patient access to the life-saving treatments and cures that the state’s life sciences professionals work diligently to discover and deliver to patients globally.

At the same time, she strives to ensure that New Jersey’s innovation ecosystem — including academic, workforce, policymaking, manufacturing, business, labor community leaders and other key stakeholders — are strategically partnering to position New Jersey as the preferred choice for companies looking to relocate or expand their operations.

Serving on the Middlesex College board and the Governor’s Economic Council, Buteas’ efforts during her first year have raised awareness among thought leaders regarding the contributions of New Jersey’s life sciences to patients worldwide and to the state’s innovation economy, and the industry’s ongoing commitment to what it has done so effectively for over a century: saving lives globally by discovering new treatments and cures right here in New Jersey.

Diane Calello

Rutgers New Jersey Medical School

Calello is the executive and medical director of the New Jersey Poison Control Center at Rutgers New Jersey Medical School. Each year, the poison control center assists approximately 50,000 residents, first responders, and health care providers with medical treatment advice and guidance on best practices for unintentional and intentional poison exposures.

Beyond its core mission and under Calello’s leadership, the poison center plays a vital role in addressing emergent public health crises across the state. For example, in June 2023, the poison center noticed an uptick in calls from hospitals regarding exposure to tianeptine products purchased at a variety of small retail outlets across the state. Upon investigation, Calello identified an unknown outbreak of tianeptine exposures causing illness, and in some cases severe illness, due to a contaminated “Neptune’s Fix” product being sold in convenience stores and gas stations. Calello notified state and federal officials, authorities and public health agencies about the center’s findings. The FDA soon issued warnings to consumers and health care providers as well as sent letters to retailers urging them to stop selling tianeptine products; and the Centers for Disease Control and Prevention published the poison center’s investigative report in its weekly epidemiologic publication, the MMWR. Calello was asked to speak at U.S. Rep. Frank Pallone’s presser introducing legislation to prohibit tianeptine from being marketed to consumers; and did national and local media interviews.

Thomas Cavalieri

Rowan University

A geriatrician and professor of medicine, Cavalieri is vice president, senior advisor for healthcare and medical education for Rowan University. Previously, he was the inaugural vice president of the Virtua Health College of Medicine and Life Sciences and chief academic officer for Virtua Health, where he worked to create a new academic health system in southern New Jersey.

For 17 years, Cavalieri served as dean of the School of Osteopathic Medicine in Stratford, first as part of the University of Medicine and Dentistry of NJ and then as the school was integrated into Rowan University. During his tenure as dean, the undergraduate curriculum was modernized, class size grew three times larger, and the SOM expanded to a second campus in Sewell, becoming the largest medical school in New Jersey. Cavalieri is also overseeing two of Rowan University’s special initiatives: a developing partnership with the Wilmington Veterans Affairs Medical Center aimed at enhancing care for South Jersey veterans, and the development of a proposed intergenerational Wellness Village on the university’s West Campus, where people can live well and age successfully. Cavalieri also serves on the Board of the Accreditation Council for Graduate Medical Education, which oversees national graduate medical education. He is helping to try to solve the physician shortage, focusing on recruiting physicians in underserved and other areas while ensuring that medical education programs maintain high standards.

Michael Charlton

AtlantiCare

As part of his drive to enhance patient care, AtlantiCare President and CEO Charlton launched VISION 2030, an aggressive six-year strategic plan aimed at transforming health care by redefining how it is measured and delivered locally, regionally and nationally.

Also under Charlton, AtlantiCare Regional Medical Center, Galloway, is undergoing a $75 million expansion that will add a new, state-of-the-art Emergency Department, a Comprehensive Command Center, 50 new private patient rooms and an expansion — to four stories — of an existing two-story patient elevator. All 50 rooms will have smart technology, which will create a better patient experience with communication; while the elevator expansion will allow for more-efficient patient transport and will provide more ways for hospital support departments to access patients.

During Charlton’s tenure, AtlantiCare became the world’s first-named partner for Oracle Health’s Clinical AI Agent, deploying advanced technology like the generative AI-based Oracle Clinical AI Agent, which enables clinicians to use voice commands to enhance their computer efficiency and focus on patient interactions. AtlantiCare providers already report a 41% reduction in total documentation time — saving 66 minutes per day. Charlton and his team have also built on a partnership with Drexel University, developing a new medical school in Atlantic City.

Chris Cozic

Genmab

When Cozic, Genmab’s global vice president of human resources, joined the leading international biotech in 2017, the company had “a few hundred people,” and its New Jersey office had fewer than 10 employees. Today, with more than 2,500 people across five countries, Cozic has helped Genmab to create an environment that supports growth while maintaining a distinctive, welcoming culture that empowers employees to innovate and collaborate with others who may not naturally be in their department, but can still bring new perspectives or dimensions to a challenge.

A recognized expert in strategic leadership, organization design, human resource management, policy development, employee relations and organizational development, Cozic knows how to build a community that responds to team members’ needs in a way that makes Genmab stronger. Programs include enhanced medical benefits — 100% of medical and vision insurance premiums are paid by the company — and family support programs for parenthood needs. Genmab also offers, at no cost to workers, benefits like an employee assistance program that provides short-term counselling, referrals, and follow-up services for personal and work-related challenges; and discount perks at a variety of retail and service providers. And as a board member at BioNJ, Cozic lends his guidance to advancing the organization’s mission of helping members help patients.

Jennifer D’Angelo

New Jersey Innovation Institute

With decades of experience in health technology and innovation, New Jersey Innovation Institute Executive Vice President, Healthcare and COO D’Angelo is a recognized leader in transforming health care through digital solutions. As chief operating officer the subsidiary of the New Jersey Institute of Technology, she oversees all core operational departments and drives strategic initiatives shaping the organization’s future. One accomplishment under her leadership is a partnership with the New Jersey Economic Development Authority to launch the NJII Venture Studio, the state’s latest Strategic Innovation Center, focused on accelerating and commercializing intellectual property.

She also leads NJII’s Healthcare Division, which includes the New Jersey Health Information Network. The statewide interoperability initiative leverages advanced networking technology and data analytics to securely connect and share data across more than 21,000 providers, facilities and health systems, reducing medical errors, enhancing data quality, and improving care coordination, ultimately making health care more efficient and cost-effective for both patients and providers. D’Angelo’s extensive experience in health tech lets her bridge the gap between technology and patient-centered care, ensuring innovation aligns with real-world clinical and operational needs.

D’Angelo is now positioning NJII for long-term growth, planning to double its impact over five years while driving AI-driven health care transformation.

James Davis

Quest Diagnostics

From spearheading the new “Purpose” of Quest Diagnostics, working together to create a healthier world one life at a time, to extending Quest’s operating presence into Canada with the acquisition of Toronto-based LifeLabs, Quest Chairman, CEO and President Davis keeps breaking new ground for the world’s leading provider of diagnostic information services.

Acting as a “North Star” for more than 55,000 employees, Davis brings the company’s many resources together for a shared mission. Under his leadership, Quest acquired Haystack Oncology in June 2023, adding cutting-edge technology for identifying cancer recurrence in early stages using a simple blood test. Quest is now making the new Haystack MRD test available domestically to medical oncologists. And in late February 2025, as part of Davis’ drive to acquire more labs, Quest announced that, under terms of a definitive acquisition agreement, the company will acquire select assets of Fresenius Medical Care’s wholly owned Spectra Laboratories, a leading provider of U.S. renal-specific laboratory testing services.

Additionally, under a separate agreement, Quest will provide comprehensive laboratory services related to end-stage kidney disease and specialized water testing for patients and providers served by dialysis centers operated by Fresenius Medical Care and its wholly owned and joint-venture partners in the United States.

Robert Davis

Merck

Davis serves as chairman and chief executive officer of Rahway-based global health care giant Merck.

The company marked a big 2024 with full-year worldwide sales of $64.2 billion, up 7% from 2023 – along with notable developments in innovation and its pipeline.

“We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including for KEYTRUDA, which continues to benefit more patients with cancer globally, the successful launch of WINREVAIR and strong performance of our Animal Health business,” said Davis in February when he announced Merck’s earnings. “We’re continuing to progress our pipeline, advance key clinical programs and augment our pipeline through promising business development. Our business remains well positioned thanks to the dedication of our talented global team – and I am more confident than ever in our long-term growth potential.”

Nandkumar Deorkar

Avantor

Deorkar is senior vice president of research and development for Avantor – overseeing the company’s Bridgewater Innovation Center, which serves as its technology-driven research and development hub. Avantor is a leading global provider of mission-critical products and services in the life sciences and advanced technology sectors.

In November, Avantor cut the ribbon on a new and expanded Innovation Center – spanning 60,000 square feet and doubling its previous lab capacity.

“We are committed to supporting our customers’ requirements and growth, and this expansion allows us to take an even more collaborative approach to deliver customized solutions that move science forward,” he said in 2023 when the project was announced. “By adding capacity, talent and capability to our Innovation Center, Avantor is in a stronger position to support the growing demands for gene therapy and mRNA workflows, facilitate pipeline project execution and enable quicker production scale-up. These enhancements will pave the way for the innovations of tomorrow.”

Joaquin Duato

Johnson & Johnson

Under the leadership of Chairman and CEO Joaquin Duato, Johnson & Johnson marked a year of progress and transformation in 2024.

Duato leads 130,000 employees who focus on tackling the toughest health challenges by developing innovative medicine and medtech solutions – operating in a broad set of high-unmet need, high-growth and high-innovation segments.

With Duato at the helm, the New Brunswick-based global health care giant is accelerating innovation, using data science and the latest technology to create breakthroughs in care – from cell therapy to robotic-assisted surgery.

In 2024, the company invested industry-leading sums in its pipeline – approximately $50 billion in R&D and M&A, including a recent acquisition agreement with Intra-Cellular Therapies. Johnson & Johnson reported sales growth in 2024 of 4.3% to $88.8 billion – and operational growth of 5.9%.

“2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating pipeline, and industry-leading investments in innovation,” said Duato in January. “With our strong financial foundation, differentiated portfolio and robust pipeline, we are well positioned to sustain the high pace of growth and innovation that is the hallmark of Johnson & Johnson.”

Matthew Edson

Rowan University

Edson is the founding dean of the Shreiber School of Veterinary Medicine of Rowan University, the first veterinary school in the state.

The new facility, located in Harrison Township, includes educational and research space as well as a multi-specialty veterinary teaching hospital that will be open to the public – with an anticipated opening in August.

This fall, the school is slated to admit its first class of nearly 70 DVM students – approximately half of which will be New Jersey residents.

In November, leaders from the school and Merck Animal Health unveiled the school’s new Shelter Medicine & Community Engagement Mobile Unit, funded through a $500,000 gift from Merck.

“We are building relationships with human provider organizations that serve community members experiencing homelessness and other barriers to care to help these community members be able to access care for their pet family members as well,” Edson said.

Perry Farhat

RWJBarnabas Health

Since 2022, Farhat has served as director of diversity and inclusion at RWJBarnabas Health System and the administrative director of the Babs Siperstein PROUD Center and the PROUD Gender Center of New Jersey.

The Babs Siperstein PROUD Center is the first primary care facility in the state that specializes in the health care needs of the LGBTQIA+ community.

Under his leadership, the PROUD Center has received awards and recognition, including an NJBIZ HealthCare Heroes Award for “Innovation.”

Farhat also serves on Gov. Phil Murphy’s LGBTQ+ Taskforce.

Earlier this year, RWJBarnabas Health hosted its 4th Annual Business Resource Group Summit – with Farhat noting its six thriving BRGs.

“Our BPN BRG maintained a mentoring program, empowering our Black employees and fostering their professional development.” Farhat wrote in a January social media post. “Our VETS BRG celebrated veteran employees and provided care kits to over 500 veteran patients honoring their service with gratitude. Our AWARE BRG delivered impactful personal and professional development workshops for women, while our PROUD BRG members reached over 7,000 individuals at 20+ LGBTQ+ events, sharing information about our specialized LGBTQ+ health care services.”

John Gallucci Jr.

JAG Physical Therapy

Gallucci founded and leads JAG Physical Therapy, one of the fastest growing comprehensive physical and occupational therapy practices providing rehabilitative care to patients and sports teams.

The organization now operates in over 150 locations throughout the region.

“Twenty-one years ago, I started the company in a small 1,800-square-foot facility in West Orange, New Jersey,” Gallucci said in September when the company opened its 150th location in New Brunswick. “I told my wife that one day, we were going to be the largest provider of outpatient physical therapy in New Jersey and New York – and here we are opening up our 150th location.”

JAG Physical Therapy also boasts several notable partnerships – as the official provider of physical therapy for organizations such as the New Jersey Devils, Columbia University Athletics, Princeton University Athletics and Seton Hall University. Last month, the company and Seton Hall extended their longstanding relationship.

“Partnering with Seton Hall over the last 20 years has been a great privilege, allowing JAG Physical Therapy to make a meaningful impact on both its athletic and academic programs,” said Gallucci.

Robert Garrett

Hackensack Meridian Health

One of the state’s most respected leaders in health care, business and beyond, Hackensack Meridian Health CEO Bob Garrett continues to take the health system to new heights. HMH boasts the state’s largest health care network: 18 hospitals, 500-plus patient care locations – with 36,000 team members and 7,000 physicians, that provide a wide range of medical services.

“We’re seeing tremendous growth,” Garrett recently told NJBIZ Editor Jeff Kanige. “We’re going to be investing $1.3 billion into Jersey Shore [University Medical Center] for a new critical care tower, new private rooms, new operating rooms. And then at JFK University Medical Center in Edison, we’re investing a lot in some of those same areas, critical care operating rooms, new emergency department, a new ambulatory cancer center that’s actually going to be opening this year. In total, over the next several years, we’re going to be investing $600 million in JFK University Medical Center.”

At last month’s New Jersey Chamber of Commerce Walk to Washington, Garrett was honored with the prestigious Thomas H. Kean Sr. Business Leadership Award. “Bob has built Hackensack Meridian Health into a national leader in the health care industry, which brings prestige and prominence to our state,” said New Jersey Chamber of Commerce President and CEO Tom Bracken. “And he has done it with competence, grace, and humility.

Warren Geller

Englewood Health

The longtime president and CEO of Englewood Health, Geller has overseen substantial growth and reach for the organization beyond its main hospital campus to better serve local communities. The health system now spans over 100 locations across five counties in North Jersey.

Geller has focused on significantly enhancing patient care services, leading to the delivery of tertiary-level care and better quality and safety outcomes. He has also driven initiatives to expand outpatient services, build an integrated physician network, bolster community relations, modernize the hospital’s campus, upgrade facilities and technology, foster health equity – and focus on population health.

These efforts have led to a variety of awards and recognition for the Geller and the health system, such as Englewood Hospital again being named as a Top Teaching Hospital for 2024 by The Leapfrog Group. It marked the seventh time the hospital earned this distinction – and it was one of only four hospitals in the state to receive this designation.

“Achieving national recognition as a top teaching hospital, again ranking our hospital among the best in the country for safe and effective care, is an honor that belongs to our entire team,” said Geller in December.

Fabian Gerlinghaus

Cellares

Gerlinghaus is the co-founder and CEO of Cellares, a biotechnology and cell therapy startup.

Last year, the company cut the ribbon on a Bridgewater facility. “Bridgewater is such an important site for us,” he said. “It’s our flagship IDMO [Integrated Development and Manufacturing Organization] Smart Factory.”

The 118,000-square-foot facility represents the first IDMO dedicated to clinical and industrial-scale cell therapy manufacturing. Since Gerlinghaus launched the San Francisco-headquartered company alongside Omar Kurdi and Alex Perch in 2019, Cellares has raised more than $355 million – growing from the three founders to a team of more than 250 employees.

Cellares expects to grow even more by the end of this year – with Bridgewater playing a critical part in that effort. In September, Cellares announced the completion of the first cGMP Cell Shuttle at the Somerset County location.

“Bringing our first cGMP Cell Shuttle online in New Jersey is a major step for Cellares and our partners,” said Gerlinghaus. “This facility showcases our innovative approach and aligns with our mission to provide life-saving cell therapies to patients in need – faster and more efficiently than ever.”

Andre Goy

Hackensack Meridian Health

Goy leads Hackensack Meridian Health’s John Theurer Cancer Center, the Garden State’s largest cancer care program.

An expert in oncology, Goy specializes in lymphoma treatment and research programs. He has been the lead investigator of three FDA-approved treatments for mantle cell lymphoma – bortezomib, lenalidomide and ibrutinib.

An example of the innovative and exciting work under his leadership – in August, the John Theurer Cancer Center announced the launch of its cancer risk and early cancer detection program, designed to better identify the risk of cancer in individuals and enable earlier diagnosis. HMH is the first in New Jersey to offer this comprehensive, early detection, and cancer risk management.

“This new program opens an entire new field in cancer, from preventing cancer in someone with genetic risk factors, to detecting cancer earlier, and reducing cancer recurrence,” said Goy. “Combining technology, genomics, and AI, our goal is to intercept cancer – including in underserved communities – by bringing new tools to people’s homes with a user-friendly platform to navigate their risk factors – and prevention or treatment options.”

Sebastian Guth

Bayer

Guth serves as COO of Bayer’s Pharmaceutical Division – responsible for commercial operations of all markets in which the company is active, including its U.S. headquarters in Whippany.

Last year, the global life sciences giant announced a streamlined leadership team aimed at ushering in its next phase of growth.

Guth works with teams globally to drive the commercial strategy to enhance customer value, maximize opportunities, and generate revenue growth and profitability around the world – while supporting the company’s strategy to substantially grow in the U.S. market.

Earlier this year, Bayer announced further progress in its pharmaceutical growth strategy with multiple regulatory filing submissions underway for key growth drivers darolutamide, finerenone and elinzanetant.

“We are successfully delivering on our ambitious business goals despite significant headwinds,” said Stefan Oelrich, member of the board of management, Bayer AG, and president of Bayer’s Pharmaceuticals Division, at a conference in January. “Our new operating model is visibly becoming a key enabler to drive growth and efficiency gains.”

Perry Halkitis

Rutgers School of Public Health

A respected leader and prolific writer, Halkitis serves as dean, Hunterdon Professor of Public Health & Health Equity, and Distinguished Professor of Biostatistics & Epidemiology at the Rutgers School of Public Health.

An infectious disease epidemiologist, applied statistician and public health psychologist, Halkitis conducts his work through research, teaching and activism.

He is also the founder and director of the Center for Health, Identity, Behavior, & Prevention Studies.

In a reflection of the recognition his work receives, the Perry N. Halkitis Endowed Chair in LGBTQ+ Public Health was established in 2023, via a $5 million gift, to ensure that LGBTQ+ health remains central to the work of the Rutgers School of Public Health for years to come.

His body of work includes authoring six books and 300 peer-reviewed academic articles. And he has served, since 2013, as the founding editor in chief of Annals of LGBTQ Public and Population Health. Halkitis serves as an expert voice and source – appearing frequently across the media spectrum.

Debbie Hart

BioNJ

Under the leadership of president and CEO Hart, BioNJ has become the trusted voice of the life sciences industry in New Jersey. From her advocacy work to fostering medical innovation and patient access while ensuring health equity and health care affordability, to hosting key industry events and serving as chair of the New Jersey Commission on Science, Innovation and Technology, Hart is recognized as a respected thought leader.

A strong advocate for advancing education, Ms. Hart sits on the board of the Blanche and Irwin Lerner Center for the Study of Pharmaceutical Management at Rutgers University Business School. She served on the advisory boards for Students 2 Science, the New Jersey Institute of Technology’s Biomedical Engineering Program, and the founding advisory board that guided the establishment of the nationally recognized Monmouth County Biotechnology High School.

Hart has testified before state and federal legislative committees, authored numerous op-eds and is a frequent speaker on issues affecting medical innovation and Patient access.

She was named one of the world’s 100 Most Influential People in Biotechnology by Scientific American Worldview; a PharmaVOICE 2021 Red Jacket Honoree and to PharmaVOICE‘s 100 Most Inspiring People list.

Leslie Hirsch

Saint Peter’s Healthcare System

In his role as president and CEO of New Brunswick-based Saint Peter’s Healthcare System, Hirsch continues to oversee the growth and evolution of the organization, which he joined in 2015.

Hirsch is a leader in the hospital field nationally and was recently elected to a three-year term on the board of trustees of the American Hospital Association, beginning January 2025. He has served several terms on the AHA’s Regional Policy Board (RPB) 2 for New Jersey, New York and Pennsylvania and began serving a three-year term as RPB 2 chair this past January. Hirsch has the distinction of being the longest serving chair of the board of trustees in the history of the New Jersey Hospital Association, having served two consecutive terms in 2015 and 2016. He was elected chair of the NJHA HealthPAC board of directors in 2023 and continues to serve in that role.

As president and CEO of Saint Peter’s, Hirsch leads one of the few remaining Catholic hospitals and single-hospital health systems in New Jersey. Over the last several years, he led a process to secure Saint Peter’s future and Catholic identity, resulting in the signing of a definitive agreement in 2024 to form a strategic partnership with Atlantic Health System. Through a comprehensive Catholic identity agreement, Saint Peter’s will remain a Catholic institution, continuing to carry on its Catholic mission after the merger with Atlantic Health, which is expected to be completed mid-2025.

Pavita Howe

BioNJ

Howe serves as vice president, innovation, and entrepreneurship for BioNJ, a trade group that serves as the voice for the state’s life science sector. In this role, Howe engages and supports the life sciences entrepreneurial community and innovation ecosystem expanding BioNJ’s outreach and collaboration with investor, academic and industry partners to increase successful entrepreneurship.

Howe’s experience as an entrepreneurial leader spans business development, marketing, strategy, program management, new products, launches, business planning and building ecosystems at startups, academic institutions and large organizations. Before joining BioNJ, Howe served as director of entrepreneurship partnerships at Rutgers University, where she worked with internal and external partners to grow Rutgers’ entrepreneurial ecosystem, bringing visibility to Rutgers affiliated startups across multiple industries, and connecting them to valuable resources at the university and across the broader New Jersey entrepreneurial network.

Before Rutgers, Howe spent her career working in marketing and leadership roles at startups in California and New Jersey. Her first entrepreneurial experience was with Forte, a San Diego-based technology startup that was acquired by Genesys, where Howe led the Marketing Launch team until the company’s acquisition by Alcatel. She served as a mentor and advisor at TechLaunch NJ and the NJ Technology Council and was a co-organizer at Morris Tech Meetup.

Sho Islam

Middlesex County Office of Business Engagement

Islam is director of the Middlesex County Office of Business Engagement and a leading figure in New Jersey’s innovation ecosystem, especially within the Life Sciences and Food & Beverage verticals. He is valued and sought-after among the startup, growth-stage, and the entrepreneurship community for providing actionable guidance and connections to build runway and accelerate growth.

He works in close partnership with leadership of New Jersey, such as those at NJEDA; the Commission on Science, Innovation and Technology; BioNJ; Healthcare Institute of New Jersey, to name a few, to ensure programs, products, and policies reflect current market needs and be conducive to retaining, attracting and growing these key industries in the Garden State. In addition, with nearly two decades of experience selling the state’s economy, Islam also has a proven track record of helping companies expand within New Jersey, as well as attracting innovative companies from domestics and international hotspots to N.J.

In his role with Middlesex County, Islan continues to sell Jersey and leads a dedicated team that supports homegrown startups, expanding businesses and attracting global enterprises to New Jersey. He and the County are also working closely with stakeholders on the HELIX-NJ project in New Brunswick.

Beyond his professional contributions, Islam volunteers on committees such as the NJBDA, and mentors first-generation college students.

Ed Jimenez

University Hospital

Jimenez was tapped in late 2022 to serve as president and CEO of University Hospital and earlier in March announced that he would leave that post for a job as president and CEO of Main Line Health, a system serving Philadelphia and its western suburbs.

At University Hospital, Jimenez was credited with several notable accomplishments. He advanced a $1.8 billion campus renovation and expansion project; achieved the No. 1 survival rate in the U.S. for liver transplantation; spearheaded an ambulatory strategy focused on network and service line expansion; and led the hospital that was named to Forbes America’s Best Employers by State for 2023

During his time in Newark, Jimenez was a mainstay on NJBIZ Power lists, including last year’s Power 100.

“I am incredibly excited and deeply honored to have the opportunity to lead Main Line Health,” Jimenez said on the occasion of his most recent move. “I look forward to working with the dedicated colleagues and medical staff who are integral to providing exceptional care to our community.”

“I am excited to welcome Ed to Main Line Health. His leadership, vision and unwavering commitment to healthcare excellence make him the ideal person to guide the System into the future,” said Steve Higgins, chair of the Main Line Health board of governors.

Robert Johnson

Rutgers New Jersey Medical School

When Johnson was named dean of Rutgers New Jersey Medical School in 2011, he was the first alumnus to serve in the role and his subsequent service, which ended last year, as interim dean of the Rutgers Robert Wood Johnson Medical School made him the first leader to oversee two medical schools at the same time. With a shortage of health care workers hitting nationwide, Johnson’s leadership at the school educating the next generation is even more important these days. A 2021 recipient of the NJBIZ Healthcare Heroes Lifetime Achievement Award, Johnson’s clinical expertise and research focuses on adolescent physical and mental health, adolescent HIV, adolescent violence, adolescent sexuality, health equity and family strengthening.

Johnson chairs the Governor’s Advisory Council on HIV/AIDS and is also chair of the Board of Deacons at Union Baptist Church in Orange. He is a fellow of the American Academy of Pediatrics, vice chair of the Community Prevention Task Force of the US Centers for Disease Control and Prevention, and a former member of the Board of the Division of Behavioral and Social Sciences and Education at the National Academies of Science. He previously served as president of the New Jersey Board of Medical Examiners, chair of the U.S. Department of Health and Human Services’ Council on Graduate Medical Education, chair of the Newark Ryan White Planning Council, and a member of the National Council of the National Institute of Mental Health.

Dr. Nizar Kifaieh and Yan Moshe

Hudson Regional Hospital

After the three-facility CarePoint Health Systems Inc. filed a Chapter 11 bankruptcy petition in November 2024, the team of President and CEO Kifaieh and Chairman Moshe turned around the beleaguered system under the Hudson Regional Hospital brand.

CarePoint’s unsustainable health care model relied largely on out-of-network patients that lacked insurance and were unable to pay for health services. But Hudson Regional adopted a different approach, combining a hard-nosed business plan with the patient concern of a physician. Under Kifaieh and Moshe, the CarePoint facilities will be integrated with Hudson Regional’s flagship Secaucus hospital. HRH’s strategy features adding specialty practices with in-network coverage for over 95% of New Jersey residents — a model that included a robust Medicare and Medicaid focus, providing substantial revenues in profitable areas to support community hospital needs.

The vision of Hudson Regional’s leadership played a crucial role in this transformation, leveraging a deep network of urgent care and medical practices that fed into the hospital system, creating a significant network benefit.

Devdatt (Dev) Kurdikar

embecta

Since its spinoff from Becton, Dickinson and Co. in 2022, President and CEO Kurdikar has successfully led embecta – the world’s leading producer of insulin injection devices – to consistently beat financial expectations in each quarter. He did so while shepherding the newly independent organization through a shopping list of challenges, beginning with the maze of requirements involved in a spinoff becoming an independent, publicly traded company. Kurdikar also steered embecta through the highest inflation in a decade, and kept his team focused on mitigating supply disruptions triggered by military conflicts, port strikes, shipping accidents and natural disasters — all while avoiding disruption to customers who depend on the company’s lifesaving insulin injection devices.

In the midst of these and other accomplishments, Kurdikar led embecta through the process of establishing its own post-spinoff independent distribution network and enterprise resource planning system. He was also instrumental in implementing embecta’s “Hungry Mindset” concept, where every employee acts with precision and urgency while continually seeking improvements across activities. Kurdikar is positioning the company for continued growth with a focus that includes three priorities: strengthening the core business of insulin injection devices; expanding the portfolio; and prioritizing free cash flow to pay down debt, which will provide flexibility for investments.

William Lewis

Insmed

Lewis is chair and CEO of Insmed. The former co-founder and leader of Aegerion Pharmaceuticals Inc. joined the Bridgewater-based global biopharmaceutical company in 2012. He became chair of the board of directors in November 2018.

Before founding Aegerion, he spent more than 10 years working in investment banking in the U.S. and Europe. He also worked for the U.S. government.

Lewis holds a Bachelor of Arts degree cum laude from Oberlin College as well as a Master of Business Administration and a Juris Doctor with Honors from Case Western Reserve University. He is a member of the board of trustees of Case Western Reserve University and a member of the board of trustees of BioNJ, the life sciences association for New Jersey. He is also chair of the board of directors of NewAmsterdam Pharma.

Last year, Insmed joined with actress Jane Seymour on a campaign to raise awareness of gender and age biases in health care. Known as “unseenism,” the social phenomenon is especially prevalent for those with chronic conditions, according to Insmed. Leading up to the initiative’s launch, Insmed conducted a nationwide survey of 2,000 participants. The effort sought to discover how the feeling can shape health decisions of people aged 40 and up.

Dr. Steven Libutti

Rutgers Cancer Institute

Under Libutti’s leadership as director, the Rutgers Cancer Institute, together with RWJBarnabas Health, retained its status as the state’s only Comprehensive Cancer Center. This year, he will preside over the opening of the Jack and Sheryl Morris Cancer Center, a $750 million project in New Brunswick.

The 520,000-square-foot facility will accommodate inpatient and outpatient treatment, research laboratories, retail space and ancillary services – and will be the state’s first free-standing cancer hospital. Meanwhile in Livingston, a $225 million cancer center is also due in 2025. That site will serve as the northern hub of RCI.

Libutti is a prominent expert in the management of neuroendocrine tumors and past president of the American Association of Endocrine Surgeons. His clinical practice focuses on gastrointestinal malignancies including cancers of the liver and pancreas.

The recipient of funding from the NCI for the past 25 years, Libutti is also a researcher whose work focuses on developing novel cancer therapies through an understanding of the tumor microenvironment as well as on a better understanding of the tumor suppressor genes.

Transformational Gift from 24 Foundation to Enhance Local Cancer Survivorship and Wellness Programs

Atrium Health News

$2 Million Investment to Support Atrium Health Levine Cancer Institute, Levine Children’s

CHARLOTTE, N.C., Jan. 24, 2025 – Adult and pediatric cancer patients will have access to enhanced survivorship and wellness programs at Atrium Health, thanks to a $2 million gift from 24 Foundation. The gift will help expand the supportive oncology programs at Atrium Health’s Levine Cancer Institute and Levine Children’s in Charlotte which provide personalized resources to patients and their caregivers throughout their cancer journey.

Collectively, 24 Foundation has invested more than $7 million in Atrium Health to help improve the quality of life for those impacted by cancer. And since its inception in 2002, the organization has raised over $29 million to support cancer navigation and survivorship programs through local and national beneficiaries.

“We are deeply grateful for our long-standing partnership with 24 Foundation and their continued dedication to our cancer patients and their care teams,” said Dr. Ruben Mesa, president of Atrium Health Levine Cancer. “Their transformational philanthropic investments continue to propel us to the forefront of supportive oncology, fueling crucial services that ensure our patients thrive throughout their treatment.”

A significant portion of the 24 Foundation gift will grow the integrative oncology program at Atrium Health Levine Cancer Institute, providing continued funding for art and music therapy; yoga and tai chi; and massage and acupuncture. The gift will also support the cancer resource center, psycho-oncology and exercise physiology programs, virtual programming, and a new full-time dietitian to work individually with oncology patients to develop personal nutrition plans.

“Patient centered care is the hallmark of Levine Cancer,” said Dr. Anthony Caprio, vice chair of Supportive Oncology at Atrium Health Levine Cancer. “We focus on the whole person and providing compassionate, safe, evidence-based approaches to address the physical, emotional and spiritual needs of our patients.”

The survivorship team at Atrium Health Levine Children’s will benefit from 24 Foundation’s ongoing support of a psychology fellow – who provided mental health care for 310 patients in 2024 – and supplies for the 24 Foundation healthy snack cart, which teaches patient and families the importance of nutrition during cancer treatment. Funds from the gift will launch a prehabilitation program to strengthen patients, physically and mentally, prior to treatment, and teambuilding opportunities for pediatric and young adult cancer survivors.

“Thanks to partners like 24 Foundation, we are offering a full range of services to our survivorship patients,” said Dr. Jen Pope, director of supportive medicine at Atrium Health Levine Children’s Cancer & Blood Disorders, whose department cared for over 700 patients in the last year. “Teamwork between health care professionals and the community ensures that our patients don’t just achieve a cure but thrive through survivorship.”

“We are deeply committed to our partnership with Atrium Health and ensuring that patients in our community have equal access to the highest quality cancer services available,” said Katherine Murphy, executive director of 24 Foundation. “I know our founder, Spencer Lueders, would agree that from the moment we first learned about the vision for Levine Cancer Institute, we knew 24 Foundation was stepping into something truly extraordinary. Thanks to the support of our sponsors and donors, we are proud to advance such impactful programs for cancer patients of all ages and see, firsthand, the difference our gifts make.”

“Defeating cancer is a team sport,” said Mesa, “and thanks to the team at 24 Foundation, we are stronger, together.”

About Atrium Health

Atrium Health is a nationally recognized leader in shaping health outcomes through innovative research, education and compassionate patient care. Based in Charlotte, North Carolina, Atrium Health is part of Advocate Health, the third-largest nonprofit health system in the United States, which was created from the combination with Advocate Aurora Health. A recognized leader in experiential medical education and groundbreaking research, Wake Forest University School of Medicine is its academic core. Atrium Health is renowned for its top-ranked pediatric, cancer and heart care, as well as organ transplants, burn treatments and specialized musculoskeletal programs. Atrium Health is also a leading-edge innovator in virtual care and mobile medicine, providing care close to home and in the home. Ranked nationally among U.S. News & World Report’s Best Hospitals in 10 pediatric specialties and for rehabilitation, Atrium Health has also received the American Hospital Association’s Quest for Quality Prize and its 2021 Carolyn Boone Lewis Equity of Care Award, as well as the 2020 Centers for Medicare & Medicaid Services Health Equity Award for its efforts to reduce racial and ethnic disparities in care. With a commitment to every community it serves, Atrium Health seeks to improve health, elevate hope and advance healing – for all, providing nearly $3 billion in free and uncompensated care and other community benefits in 2023

About 24 Foundation

24 Foundation is a registered 501(c)(3) non-profit charity located in Charlotte, N.C. with a mission to inspire and engage communities to make an immediate impact on the lives of people affected by cancer. Funds raised support organizations dedicated to cancer navigation and survivorship including Atrium Health’s Levine Cancer Institute and Levine Children’s Hospital. Since 2002, more than 29,000 participants in its signature 24 Hours of Booty fundraiser have raised more than $29 million, with an ultimate goal of providing supportive oncology programs and services for all. For more information, visit 24foundation.org.

Owners, Kristin Oja and Cam Oja, in soon-to-be Nashville space.

As millions embark on their 2025 health and wellness journeys, STAT Wellness is leading the charge with its innovative approach to sustainable health. Combining personalized functional medicine with science-backed movement, STAT Wellness is empowering patients to address the root causes of health concerns and achieve long-term wellness.

Addressing health from the root

Founded by award-winning entrepreneur Kristin Oja, STAT Wellness offers a comprehensive approach to health by tackling the “why” behind symptoms and the “how” of sustainable habits. With three successful locations and a fourth opening in Nashville in May 2025, the fast-growing brand is making holistic care accessible to nearly 8,000 patients nationwide.

Owners, Kristin Oja and Cam Oja, in soon-to-be Nashville space.

“Our Medicine + Movement model bridges the gap between functional medicine and fitness, helping patients not only meet their goals but exceed them,” said Oja. “This approach gives individuals the tools to achieve transformative, lasting health.”

Innovative services driving growth

STAT Wellness’s unique model integrates functional medicine with science-driven movement and therapies to deliver unmatched results.

Advertisement – scroll for more content

STAT Wellness Logo

• Functional medicine: Comprehensive health assessments and root-cause care plans help optimize patient health.

• Science-backed movement: Functional strength training programs designed by Doctors of Physical Therapy focus on long-term fitness and injury prevention.

• IV and IM therapy: Targeted solutions enhance energy, immunity, and longevity.

Where Functional Medicine meets Movement.

With a team of 40 specialists, including Functional Medicine Providers, Dietitians, Physical Therapists, and Health Coaches, STAT Wellness delivers individualized care. Transparent pricing and flexible membership or à la carte options ensure accessibility for every patient.

A leader in integrative health care

Kristin Oja’s vision and leadership have propelled STAT Wellness into the national spotlight. Named one of Ernst & Young’s Winning Women and featured in prominent outlets like The Washington Post and The Oprah Magazine, Oja has guided the company to 174% growth. STAT Wellness has also earned the title of Best Functional Medicine Practice in Atlanta, cementing its reputation as an industry leader.

“Functional medicine isn’t a luxury—it’s essential for achieving true wellness,” said Oja. “We’re committed to making personalized care accessible, empowering patients to take control of their health in meaningful ways.”

Empowering patients nationwide

As STAT Wellness continues its expansion, its mission remains clear: to provide science-backed, holistic care that helps patients thrive. With its innovative approach, STAT Wellness is redefining what it means to prioritize health, making 2025 a year of transformative care for individuals nationwide.

Related

The Healthcare Technology Report is pleased to announce its annual awards for The Top 100 Healthcare Technology Companies. This year’s awardees were selected based on a methodical review of nomination submissions as well as further in-depth research into each candidate’s products and solutions, corporate track record, management team caliber, and organizational depth, among other factors.

These companies are leading a charge that sees the industry headed toward a $1 trillion market size by the end of the decade. From software to medical devices to biotechnology to wearables and beyond, these companies showcase the best of what modern ingenuity has to offer for every living citizen around the globe. Among the various innovative technologies represented, it is worth highlighting that this year saw Artificial Intelligence make its way into many different areas of the healthcare sector.

This year, our No. 1 company is Regeneron, which rose to the top with strong sales from its wet-age related macular degeneration drug Eylea HD and which boasts a market cap of more than $90 billion. The Tarrytown, New York-based company, which became a household name during the COVID-19 pandemic, has landed atop our rankings for the first time. Regeneron sits right beside innovators like Melville, New York-based Henry Schein (No. 3), which reached $12.3 billion in sales in 2023 and whose CEO, Stanley Bergman, also tops our list of the Top 25 Medical Device Executives of 2024.

Also deserving of special recognition is LifeLabs (No. 5), which. serves more than 8 million Canadians, earning special recognition for two consecutive years. Not to be outdone, Mountain View, California-based Omnicell (No. 9) continues to grow with its goal of creating the ultimate Autonomous Pharmacy, jumping more than 40 spots since its last appearance in our rankings.

Please join us in recognizing The Top 100 Healthcare Technology Companies of 2024.

1. Regeneron Pharmaceuticals

A rising tide lifts all boats, and 2024 has marked a massive year for our No. 1 Healthcare Technology company. Regeneron’s wet-age related macular degeneration drug Eylea HD netted $392 million in sales in the third quarter alone, leading the company to an 11 percent bump in Q3 revenues compared to 2023. Sales of Duplixent rose 23 percent compared with last year in the third quarter, while sales of Libtayo, a treatment for squamous cell skin cancer, rose 24 percent over the same period.

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, its unique ability to repeatedly translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in their laboratories. Its medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

The technology: Regeneron pushes the boundaries of scientific discovery and accelerates drug development using proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. The company is shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center and pioneering genetic medicine platforms, enabling them to identify innovative targets and complementary approaches to potentially treat or cure diseases.

2. Medtronic

In April, the FDA approved Inceptiv, a device from our No. 2 Healthcare Technology company, Medtronic. Inceptiv is a small device implanted in the torso, reaching the spinal cord, that alleviates chronic pain by providing responsive counter-stimulation.

Medtronic, a leading global healthcare technology company headquartered in Galway, Ireland, is focused on addressing significant health issues facing humanity. Medtronic unites a team of more than 95,000 employees across more than 150 countries, and its extensive portfolio of technologies and therapies addresses 70 different health conditions, including cardiac devices, surgical robotics, insulin pumps, surgical tools, and patient monitoring systems.

The mission: Driven by a commitment to helping those in need, Medtronic transforms the lives of two people every second, every hour, and every day.

Milestone: Recently, Medtronic has expanded its AiBLE spine surgery ecosystem with new technologies and formed a partnership with Siemens Healthineers. Additionally, the company has received FDA approval for its Simplera Continuous Glucose Monitoring (CGM) system and entered a global partnership with Abbott, enhancing its diabetes management solutions to meet individuals at various stages of their diabetes journey.

Past Rankings from The Healthcare Technology Report:

The Top 100 Healthcare Technology Companies of 2023 (No. 1)

3. Henry Schein

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for healthcare professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the company’s network of trusted advisors provides more than one million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Its Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

The technology: Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers. A Fortune 500 Company and a member of the S&P 500 index, Henry Schein is headquartered in Melville, NY, and has operations or affiliates in 33 countries and territories. The company’s sales reached $12.3 billion in 2023, and have grown at a compound annual rate of approximately 11.5 percent since Henry Schein became a public company in 1995.

4. Access Healthcare

Access Healthcare is a provider of revenue cycle management services, specializing in medical billing, coding, and accounts receivable management. With a global presence, the company is focused on delivering effective solutions to healthcare organizations.

Operating from 23 delivery centers across 11 cities in the United States, India, and the Philippines, Access Healthcare employs more than 27,000 professionals. The company offers a range of services, including business process outsourcing, application services, and robotic process automation tools tailored for hospitals, health systems, providers, payers, and related service providers.

Based in Dallas, Texas, Access Healthcare supports more than 500,000 healthcare providers through more than 130 clients. The company processes over $120 billion in revenue annually and assigns medical codes to more than 40 million charts each year.

The technology: Access Healthcare has developed a proprietary robotic process automation platform, implementing over 3,500 virtual bots across its service verticals to improve operational efficiency. The organization holds multiple certifications, including HITRUST R2, PCI DSS, SOC, ISO 27001, and ISO 9001, ensuring the security, availability, and confidentiality of sensitive health information.

Past Rankings from The Healthcare Technology Report:

The Top 100 Healthcare Technology Companies of 2023 (No. 3)

The Top 100 Healthcare Technology Companies of 2022 (No. 6)

5. LifeLabs

LifeLabs is Canada’s leading provider of laboratory diagnostic information and digital health solutions, empowering healthcare professionals and patients to make informed health decisions. Operating Canada’s first commercial genetics lab and the largest online patient portal, LifeLabs connects more than 8 million Canadians to their health information. With cutting-edge diagnostics and a commitment to service excellence, LifeLabs is shaping the future of healthcare.

The technology: Offering a comprehensive suite of diagnostic, genetic, and digital health services, LifeLabs excels in routine and specialized testing, non-invasive prenatal testing, pharmacogenomics, and hereditary cancer screening. With advanced digital health solutions, LifeLabs provides secure online access to test results, improving patient engagement and healthcare delivery.

The mission: LifeLabs was chosen by more than 25,000 Canadians for its caring and helpful frontline staff. 84 percent of respondents highlighted LifeLabs’ values, recognizing its focus on accessibility, inclusivity, and high standards

6. PHC Holdings Corporation

PHC Group is a global collection of healthcare companies that provide precision technology for diabetes management, health IT, diagnostics, and life sciences. It’s best-in-class products and services are used by patients, healthcare professionals and researchers in more than 125 countries for advancing research, diagnosis, and medical treatment.

7. Integra LifeSciences

Integra LifeSciences is a leading global medical technology company innovating new treatment pathways in surgical, neurologic and regenerative care to advance patient outcomes and set new standards of care. The company offers a broad portfolio of products and innovative solutions for dural access and repair, cerebral spinal fluid management, neuro-critical and surgical care. Its regenerative tissue technologies include products that address soft tissue, peripheral nerve and tendon repairs and for the treatment of acute and chronic wounds, burns, as well as for plastic and reconstructive surgery.

The technology: Founded in 1989 with the acquisition of an engineered collagen technology platform used to repair and regenerate tissue, Integra has developed numerous product lines from this technology for applications ranging from burn and deep tissue wounds to the repair of dura mater in the brain, as well as nerves and tendons. It has since expanded its base regenerative technology business to include surgical instruments, neurosurgical and ear, nose and throat technologies and advanced wound care products through global acquisitions and product development to meet the evolving needs of customers and enhance patient care.

The mission: Today, Integra LifeSciences has grown immensely, with more than 4,000 employees worldwide as well as offices, manufacturing and research facilities in Asia, Australia, Europe, Middle East, and the Americas. Integra products are ubiquitous in many hospital intensive care units and operating rooms around the world.

Milestone: In November, the company announced that Mojdeh Paul would take over as CEO in January 2025.

Past Rankings from The Healthcare Technology Report:

The Top 25 Medical Device Companies of 2024 (No. 3)

The Top 100 Healthcare Technology Companies of 2022 (No. 8)

The Top 100 Healthcare Technology Companies of 2021 (No. 2)

8. Lumeris

Lumeris is a value-based care managed services operator that was founded on the model of Essence Healthcare, a fully insured Medicare Advantage plan established in St. Louis in 2004 by a physician group. Since its inception, Essence Healthcare has prioritized a patient-first clinical approach, achieving strong financial results and consistently earning a 5-star rating from the Centers for Medicare and Medicaid Services (CMS). In 2011, Lumeris was launched to expand this model, acting as a co-operating, risk-sharing partner for health systems and physician groups.

The technology: The company aligns providers and payers through advanced technologies, streamlined processes, and actionable information to deliver high-quality, cost-effective care. Lumeris emphasizes consumer satisfaction and physician engagement, setting it apart in the healthcare landscape.

Partner spotlight: Lumeris’s partnership with Essence Healthcare, its inaugural client, serves over 60,000 Medicare members across Missouri and Illinois. Over the past decade, Lumeris has maintained an average CMS rating of 4.5 stars, alongside leading scores for consumer and physician satisfaction. The company has also achieved improved clinical outcomes while reducing costs.

Past Rankings from The Healthcare Technology Report:

The Top 25 Healthcare Software Companies of 2024 (No. 4)

9. Omnicell

Since 1992, Omnicell has been dedicated to transforming pharmacy care through outcomes-centric innovation that optimizes clinical and business outcomes across all healthcare settings. With a comprehensive portfolio of robotics, smart devices, intelligent software, and expert services, Omnicell empowers healthcare facilities worldwide to reduce costs, enhance labor efficiency, and establish new revenue streams. Omnicell’s solutions improve supply chain control and support regulatory compliance, all while advancing the vision of the Autonomous Pharmacy.

The mission: As a leader in medication management technology, Omnicell is committed to driving the future of pharmacy care, ultimately improving patient safety and healthcare delivery.

Past Rankings from The Healthcare Technology Report:

The Top 100 Healthcare Technology Companies of 2021 (No. 50)

10. Globus Medical

Globus Medical is a global musculoskeletal company focused on addressing unmet clinical needs and improving patient lives. Founded in 2003, the company has quickly become the fastest-growing entity in the orthopedic sector, concentrating on advancing surgical techniques and outcomes. Globus Medical is known for its innovative use of engineering and technology to promote pain-free, active lives for patients. With a product suite that includes spine, orthopedic trauma, joint reconstruction, biomaterials, and enabling technologies, Globus Medical is leading advancements in the musculoskeletal field.

Milestone: Recently, Globus Medical launched the ADIRA XLIF Plate System, its first product compatible across an expanded lateral interbody portfolio. Additionally, the company received FDA 510(k) clearance for its ExcelsiusFlex and ACTIFY 3D Total Knee System. This new robotic navigation platform enhances the existing Excelsius ecosystem, providing surgeons with improved control, resection accuracy, and procedural flexibility in Total Knee Arthroplasty.

Past Rankings from The Healthcare Technology Report:

The Top 25 Medical Device Companies of 2024 (No. 6)

11. Jazz Pharmaceuticals

Jazz Pharmaceuticals is a global biopharmaceutical company committed to innovating and transforming the lives of patients and their families. Established in 2003, the company focuses on developing life-changing medicines for individuals facing serious diseases, particularly where there are limited or no therapeutic options available. By harnessing biopharmaceutical discoveries, Jazz Pharmaceuticals strives to provide people worldwide with the chance to redefine their possibilities.

The technology: The company boasts a diverse portfolio of marketed medicines, with leading therapies for sleep disorders and epilepsy, along with a growing range of cancer treatments. Jazz’s patient-focused and science-driven approach fuels pioneering advancements in research and development, particularly in oncology and neuroscience, ensuring a robust pipeline of innovative therapeutics.

The mission: With approximately 3,300 employees, Jazz fosters a highly collaborative culture, emphasizing core values such as integrity, collaboration, passion, innovation, and the pursuit of excellence.

Past Rankings from The Healthcare Technology Report:

The Top 100 Healthcare Technology Companies of 2022 (No. 9)

The Top 100 Healthcare Technology Companies of 2021 (No. 54)

12. Penumbra

Penumbra, headquartered in Alameda, California, is a leading thrombectomy company focused on developing technologies for medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. With approximately 4,000 employees, Penumbra designs, develops, manufactures, and markets a range of products, including its Computer Assisted Vacuum Thrombectomy (CAVT) technologies, which enable the efficient removal of blood clots from head to toe.

Penumbra serves healthcare providers, hospitals, and clinics in over 100 countries, aiming to improve patient outcomes and quality of life. The company primarily distributes its products through a direct sales organization in the United States, most of Europe, Canada, and Australia, as well as through select international distributors.

Milestone: Recently, Penumbra received CE Mark approval in Europe for its CAVT technologies, Lightning Flash 2.0 and Lightning Bolt 7. Additionally, in August 2024, its board of directors approved a share repurchase authorization of up to $200 million, allowing the company to repurchase its common stock through various means, including open market purchases and privately negotiated transactions.

Past Rankings from The Healthcare Technology Report:

The Top 25 Medical Device Companies of 2024 (No. 4)

The Top 100 Healthcare Technology Companies of 2022 (No. 14)

13. PCI Pharma Services

PCI is a leading global CDMO, providing integrated end-to-end drug development, manufacturing and packaging solutions to increase product speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the delivery of supply chain healthcare services.

The mission: With 30 sites across Australia, Canada, North America, the UK and Europe and over 5,200 dedicated employees, its mission is to bring life-changing therapies to patients. Leading technology and continued investment enable the company to deliver development to commercialization solutions throughout the product lifecycle, collaborating with clients to improve the lives of patients globally.

Past Rankings from The Healthcare Technology Report:

The Top 100 Healthcare Technology Companies of 2023 (No. 6)

14. Corza Medical

Since its founding in 2021, Corza Medical has rapidly emerged as a leader in the medical-devices technology and innovative surgical solutions sector. The company focuses on developing cutting-edge solutions within four business categories: Ophthalmology, Wound Closure, Biosurgery, and Biomedical Textiles. Corza Medical has also been recognized for its comprehensive approach to excellence in customer service and partnerships, which has been a key factor in its swift ascent within the industry.

Partner spotlight: With a global team of approximately 3,000 employees supporting clinicians, distributor-partners, and medical device companies worldwide, Corza Medical provides healthcare professionals a platform of surgical technologies with many industry-leading brands, including Quill barbed sutures, Sharpoint Plus and Look™️ surgical sutures, Katena®️ reusable and Blink™️ single-use ophthalmic instruments, Barron corneal transplant devices, Sharpoint microsurgical knives, and the TachoSil fibrin sealant patch.

15. Aspen Medical

Founded in 1994, Aspen Medical Products is an industry leader in the development and manufacturing of spinal orthopedics and pain therapy solutions.

The mission: Designed to restore function and alleviate pain, Aspen’s products address a variety of patient needs across the continuum of care to help them resume activities of daily living. Headquartered in Irvine, California, Aspen has local sales representation throughout the U.S. and internationally.

The technology: Known for its expertise in healthcare delivery in remote, challenging, and under-resourced settings, Aspen Medical recently launched a bracing solution aimed at mitigating Proximal Junctional Kyphosis (PJK), advancing its role in specialized healthcare.

Past Rankings from The Healthcare Technology Report:

The Top 25 Medical Device Companies of 2024 (No. 15)

16. embecta

embecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships, and the passion of more than 2,000 employees around the globe. With the creation of the first insulin delivery device in 1924, embecta delivered an innovation that moved the management and treatment of diabetes forward. Today, the company produces approximately 8 billion insulin injection devices each year, including pen needles and syringes, and serves an estimated 30 million people in more than 100 countries around the world.

The mission: Whether newly diagnosed or transitioning to a new line of therapy, embecta is focused on making everyday experiences as comfortable and convenient as possible, while also working to advance a new generation of life-changing solutions.

17. LivaNova

LivaNova is a global medical technology company with nearly five decades of experience and a commitment to improving the lives of patients worldwide. With a diverse product portfolio and a strong market presence, LivaNova provides technologies and treatments that deliver clinical and economic value to patients, healthcare professionals, and healthcare systems.

The mission: As a leader in cardiopulmonary and neuromodulation, LivaNova develops products and therapies that have a meaningful impact on patients’ lives, solidifying its position in the medical technology and services sector. Headquartered in London, LivaNova employs approximately 2,900 individuals across more than 100 countries.

18. Honor Technology

Honor is changing the way people care for care professionals, aging adults and their families. By bringing together technology solutions and best-in-class home care, Honor and its subsidiaries support the work of over 100,000 care professionals and meet the expanding needs of millions of older adults around the world.

The mission: When Seth Sternberg saw that his mom was starting to slow down, he brought the idea of caring for aging adults to Sandy Jen, Monica Lo, and Cameron Ring. Together, they founded Honor in 2014, scaled a home care agency, built a national network of agencies, and developed a technology platform to strengthen the relationship between Care Pro and Client.

19. Privia Health

Privia Health is a technology-driven, national physician enablement company headquartered in Arlington, Virginia, with approximately 1,000 employees. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering high-value care in both in-person and virtual settings.

The mission: At the core of Privia Health is the Privia Platform, supported by industry talent and physician leadership. This platform features scalable operations and cloud-based technology designed to reduce healthcare costs, achieve better health outcomes, and improve the well-being of patients and providers. Through its physician groups, accountable care organizations, and population health management programs, Privia Health partners with health plans, health systems, and employers to align reimbursements with quality and outcomes.

20. CareDx

CareDx, headquartered in Brisbane, California, employs approximately 700 individuals and is a leader in precision medicine solutions for transplant patients and their caregivers. The company specializes in the discovery, development, and commercialization of clinically differentiated healthcare solutions, offering testing services, products, and digital healthcare solutions that support patients throughout their pre- and post-transplant journeys.

The mission: As the primary provider of genomics-based information for transplant patients, CareDx is dedicated to improving the lives of organ transplant recipients through non-invasive diagnostics. The company utilizes advancements in genomics and bioinformatics technology, focusing on generating clinical evidence through trials and registries. This commitment positions CareDx at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions.

Past Rankings from The Healthcare Technology Report:

The Top 25 Biotechnology Companies of 2024 (No. 6)

21. Merit Medical Systems

Founded in 1987, Merit Medical Systems, is a global healthcare company dedicated to the development, manufacture, and distribution of proprietary disposable medical devices utilized in interventional, diagnostic, and therapeutic procedures. The company’s focus areas include cardiology, radiology, oncology, critical care, and endoscopy. With a robust sales force and clinical support team exceeding 700 professionals, Merit serves hospitals worldwide, employing approximately 7,000 individuals across its various facilities.

The mission: Merit Medical understands the evolving needs of its customers and is committed to innovating and delivering medical solutions that significantly enhance patient care.

Milestone: Recently, Merit Medical has taken strategic steps to expand its portfolio by executing an asset purchase agreement with EndoGastric Solutions for approximately $105 million. This acquisition includes the EsophyX Z+ device, a groundbreaking minimally invasive treatment option for patients suffering from gastroesophageal reflux disease (GERD).

Additionally, Merit has announced the U.S. commercial release of the basixSKY Inflation Device, the latest addition to its comprehensive inflation device portfolio, alongside the launch of the Micro ACE Advanced Micro-Access System, which provides an innovative solution for achieving successful micro-access in challenging cases. The company operates manufacturing and support facilities in key locations, including South Jordan, Utah, Pearland, Texas, and international sites in the Netherlands, France, Ireland, China, and beyond.

Past Rankings from The Healthcare Technology Report:

The Top 25 Medical Device Companies of 2024 (No. 10)

22. Castle Biosciences

Castle Biosciences is a diagnostics company focused on transforming disease management with a patient-centric approach. By prioritizing the needs of patients who benefit from advanced diagnostic tests, clinicians who rely on these tests for informed decision-making, and the employees who drive innovation, Castle Biosciences aims to enhance the overall healthcare experience while providing value to its investors.

The technology: The company has a portfolio of commercial and pipeline tests that address unmet clinical needs across the patient care continuum. Castle Biosciences currently markets six proprietary tests that tackle clinical questions and treatment challenges faced by physicians, particularly in dermatologic cancers, uveal melanoma, Barrett’s esophagus, and mental health.

Headquartered in Friendswood, Texas, Castle Biosciences operates laboratories in Phoenix, Arizona, and Pittsburgh, Pennsylvania, ensuring a broad reach for its diagnostic solutions.

Past Rankings from The Healthcare Technology Report:

The Top 25 Consumer HealthTech Companies of 2024 (No. 12)

The Top 100 Healthcare Technology Companies of 2021 (No. 7)

23. Endologix

Endologix is a California-based global medical device company focused on enhancing patient outcomes through innovative therapies for the interventional treatment of vascular diseases. The company offers a therapeutic portfolio that addresses clinically relevant unmet needs in the medical community, developing products designed to treat a wide spectrum of vascular conditions, including abdominal aortic aneurysms and lower limb peripheral vascular disease.

The technology: Among its commercial offerings are the AFX 2 Endovascular AAA System, the ALTO Abdominal Stent Graft System, and the DETOUR System, all of which are engineered to deliver excellent clinical outcomes through meticulous attention to product design, manufacturing, and training, supported by industry-leading clinical evidence.

The mission: Endologix is wholly owned by Deerfield Management, an investment management firm dedicated to advancing healthcare through strategic investment, information, and philanthropy. With offices and manufacturing facilities in Irvine, Milpitas, and Santa Rosa, California, Endologix is committed to providing physicians with devices tailored to each patient’s needs.

24. Blueprint Medicines

Blueprint Medicines is a global biopharmaceutical company focused on inventing life-changing medicines to alleviate human suffering. With a core emphasis on allergy/inflammation and oncology/hematology, the company addresses significant medical challenges by targeting the root causes of diseases through deep scientific expertise and innovative drug discovery.

The technology: The company has achieved notable success with two approved medicines, including AYVAKIT/AYVAKYT (avapritinib) for systemic mastocytosis (SM), available in the U.S. and Europe. Blueprint Medicines is expanding its impact by advancing a robust pipeline of investigational therapies for mast cell diseases such as SM and chronic urticaria, as well as breast cancer and other solid tumors.

The mission: Headquartered in Cambridge, Massachusetts, Blueprint Medicines employs approximately 700 people and is dedicated to making a meaningful impact in the communities it serves.

25. Denali

Denali Therapeutics, a biopharmaceutical company headquartered in South San Francisco, is advancing a diverse pipeline of therapies specifically engineered to overcome the blood-brain barrier, focusing on treatments for neurodegenerative and lysosomal storage diseases. With an emphasis on genetically validated targets, Denali pioneers innovative delivery mechanisms for therapeutics and utilizes biomarkers to ensure precise pathway and target engagement during development.

The mission: Denali’s core mission is to break down longstanding challenges in scientific research and clinical practice to bring effective and safe medicines to patients and their families affected by neurodegenerative conditions. The company’s culture is rooted in scientific rigor, impact-focused innovation, and a collaborative environment that values diverse expertise and backgrounds. This unity drives their purpose to combat neurodegeneration effectively.

Milestone: In recent developments, the FDA has selected Denali’s DNL126 (ETV) for the START pilot program, an initiative aimed at expediting the development of therapies for rare diseases, marking a significant milestone in Denali’s commitment to addressing urgent unmet medical needs.

Past Rankings from The Healthcare Technology Report:

The Top 100 Healthcare Technology Companies of 2023 (No. 71)

26. BillionToOne

BillionToOne, headquartered in Menlo Park, California, is a pioneering precision diagnostics company dedicated to enhancing the accuracy, efficiency, and accessibility of molecular diagnostics. With its patented Quantitative Counting Technology (QCT), BillionToOne stands out as the only provider of multiplex technology capable of counting DNA molecules at the single-molecule level.

The mission: This innovative molecular counting platform aims to significantly improve disease detection and advance the field of diagnostics, fulfilling the company’s mission to empower healthcare providers and patients alike through more precise diagnostic tools.

Milestone: BillionToOne raised $130 million in a Series D funding round in June to help further scale its prenatal screening and oncology diagnostics businesses. The round pushed the total amount of cash raised by the company above $400 million and the company’s valuation above $1 billion. Additionally, BillionToOne named three new executives in November: Judy Wong joined as Vice President, Controller; Alex Bisignano as Vice President of Business Development; and Susan Lin as Vice President of Information Systems.

Past Rankings from The Healthcare Technology Report:

The Top 25 Biotechnology Companies of 2024 (No. 9)

The Top 100 Healthcare Technology Companies of 2022 (No. 57)

27. Spring Health

Spring Health is a global behavioral health solution that delivers financial returns for organizations and aims to improve lives. Through its Precision Mental Healthcare approach, Spring Health connects individuals and families with personalized interventions and culturally-responsive mental health care. Certified by the Validation Institute, the company shows net savings for its customers.

The mission: Spring Health modernizes employer behavioral health benefits with a comprehensive solution for employee mental wellbeing. It serves as a single entry point for various care options, including digital exercises, Employee Assistance Programs (EAP), coaching, therapy, and medication management.

The technology: Using proprietary assessments and machine-learning technology, Spring Health identifies individuals’ needs and matches them with tailored care plans. Each member is supported by a Care Navigator who helps schedule appointments and connects them with experts in work-life, legal, and financial services.

Milestone: Recently, Spring Health announced $100 million in Series E funding to accelerate growth and expand global access to mental healthcare. The acquisition of Bloom’s self-guided digital intervention content enhances its therapy solutions, advancing its vision to personalize mental healthcare with engaging digital tools. Headquartered in New York City, Spring Health employs approximately 2,600 professionals focused on improving behavioral health.

Past Rankings from The Healthcare Technology Report:

The Top 25 Consumer HealthTech Companies of 2024 (No. 3)

The Top 100 Healthcare Technology Companies of 2023 (No. 22)

28. Ardelyx

Ardelyx is a biopharmaceutical company committed to discovering, developing, and commercializing innovative, first-in-class medicines that address significant unmet medical needs.

Partner spotlight: With a strong focus on advancing patient care, Ardelyx has successfully developed two commercial products approved in the United States: IBSRELA (tenapanor) for irritable bowel syndrome with constipation and XPHOZAH (tenapanor) for hyperphosphatemia. Through strategic global partnerships, Ardelyx has expanded the reach of tenapanor internationally. In Japan, Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia, while a New Drug Application for tenapanor is under review in China through Fosun Pharma. Additionally, Knight Therapeutics oversees the commercialization of IBSRELA in Canada.

The mission: Ardelyx’s innovative approach to drug discovery has empowered its scientists to explore novel biological mechanisms, resulting in medicines that aim to improve patient outcomes. This commitment to patient care and medical advancement underscores Ardelyx’s mission to make a meaningful impact on the lives of patients worldwide.

Past Rankings from The Healthcare Technology Report:

The Top 100 Healthcare Technology Companies of 2021 (No. 21)

29. Tebra

Tebra, headquartered in Southern California, empowers independent healthcare practices with cutting-edge AI and automation to drive growth, streamline care, and boost efficiency. Its all-in-one EHR and billing platform delivers everything needed to attract and engage patients, including online scheduling, reputation management, and digital communications. Inspired by “vertebrae,” the name embodies its mission to be the backbone of healthcare success.

The mission: With over 165,000 providers and 190 million patient records, Tebra is redefining healthcare through innovation and a commitment to customer success.

Milestone: In August, Tebra implemented numerous product improvements intended to optimize workflows and enhance the user experience. These improvements encompass improved, easy-to-read pediatric growth charts and immediate access to patient communications from the clinical chart (currently in beta).

Past Rankings from The Healthcare Technology Report:

The Top 25 Healthcare Software Companies of 2024 (No. 6)

The Top 100 Healthcare Technology Companies of 2023 (No. 9)

The Top 100 Healthcare Technology Companies of 2022 (No. 34)

30. Zynex Medical

Zynex, founded in 1996, engineers, manufactures, and markets neuro-diagnostics, stroke rehabilitation, pain management, and cardiac monitoring devices within three subsidiaries. Zynex Medical is a provider of electrotherapy products for home use, Zynex Monitoring Solutions develops products for cardiac monitoring for use in hospitals, and Zynex NeuroDiagnostics develops devices for EMG and EEG diagnostic applications within neurology disciplines.

The mission: Zynex Medical’s product line is fully developed, FDA/CE cleared, commercially sold, and has been developed to uphold the company’s mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. Zynex Monitoring Solutions and Zynex NeuroDiagnostics are currently both in the development stages without any significant revenues.

Past Rankings from The Healthcare Technology Report:

The Top 25 Medical Device Companies of 2024 (No. 9)

The Top 100 Healthcare Technology Companies of 2023 (No. 23)

The Top 100 Healthcare Technology Companies of 2022 (No. 33)

31. Tandem Diabetes Care

Tandem Diabetes Care is a global leader in insulin delivery and diabetes technology headquartered in San Diego, California. The company specializes in manufacturing and selling advanced automated insulin delivery systems designed to alleviate the burden of diabetes management. By creating innovative solutions, Tandem enhances the quality of life for patients, their families, and healthcare providers.

The technology: The company’s product portfolio includes the Tandem Mobi system and the t:slim X2 insulin pump, both equipped with Control-IQ advanced hybrid closed-loop technology. Notably, Tandem recently announced the commercial launch of the Tandem Mobi, recognized as the world’s smallest and most durable automated insulin delivery system, tailored for individuals living with diabetes.

Milestone: John Sheridan, President and CEO of Tandem Diabetes Care, was named to the Healthcare Technology Report’s list of the Top 25 Medical Device Executives of 2024. Additionally, Sheridan said in a November earnings call that the demand for the company’s insulin pumps for Type-2 diabetes had surpassed expectations.

Past Rankings from The Healthcare Technology Report:

The Top 25 Medical Device Companies of 2024 (No. 12)

The Top 100 Healthcare Technology Companies of 2022 (No. 21)

32. Biodesix

Biodesix is a diagnostic solutions company based in Louisville, Colorado, specializing in tests for patients with lung diseases.

The technology: The company offers five Medicare-covered tests, including the blood-based Nodify Lung Nodule Risk Assessment, which features the Nodify XL2 and Nodify CDT tests. These tests evaluate the risk of malignancy in pulmonary nodules, allowing physicians to triage patients and determine appropriate treatment paths.

In addition to these services, Biodesix provides the IQLung test portfolio for lung cancer patients, which includes the GeneStrat targeted ddPCR test, the GeneStrat NGS test, and the VeriStrat test. This portfolio supports treatment decisions across all stages of lung cancer and facilitates personalized treatment options.

Past Rankings from The Healthcare Technology Report:

The Top 100 Healthcare Technology Companies of 2022 (No. 59)

33. Rocket Pharma

Rocket Pharmaceuticals, based in Cranbury, New Jersey, is a late-stage biotechnology company with 300 employees focused on developing sustainable genetic therapies for complex and rare disorders. The company employs an innovative multi-platform approach to create targeted gene therapies, offering potentially transformative treatments that enable individuals with severe rare diseases to live longer, healthier lives.

The technology: Rocket’s lentiviral vector-based hematology portfolio includes late-stage programs for critical conditions such as Fanconi Anemia (FA), which can cause bone marrow failure and cancer; Leukocyte Adhesion Deficiency-I (LAD-I), a severe genetic disorder leading to life-threatening infections; and Pyruvate Kinase Deficiency (PKD), a red blood cell disorder resulting in varying degrees of anemia.

In the cardiovascular space, Rocket’s adeno-associated viral vector-based portfolio features a late-stage program for Danon disease, a serious heart condition that leads to thickening of the heart muscle. It also includes an early-stage program for PKP2-arrhythmogenic cardiomyopathy (ACM), which can cause life-threatening arrhythmias, and a pre-clinical program targeting BAG3-associated dilated cardiomyopathy (DCM), characterized by enlarged ventricles.

Past Rankings from The Healthcare Technology Report:

The Top 25 Biotechnology Companies of 2024 (No. 11)

The Top 100 Healthcare Technology Companies of 2023 (No. 44)

34. Consensus Cloud Solutions

Consensus Cloud Solutions, Inc. is a global leader in digital cloud fax technology. With over 25 years of success with eFax at its core, the company has evolved into a trusted provider of interoperability solutions, leveraging artificial intelligence and secure data exchange to transform digital information, automate critical workflows, and maximize operational efficiencies. Consensus maintains industry-leading compliance standards, making it a preferred partner for heavily regulated industries including healthcare, the public sector, financial services, insurance, real estate, and manufacturing.

The technology: Consensus offers a versatile suite of technologies, each functioning as a standalone solution or seamlessly integrating into a comprehensive platform to address the critical challenges of healthcare data communication and management. This includes secure cloud faxing, electronic signatures, a robust integration engine for HL7, FHIR, and effortless conversion between various communication protocols, and an intelligent data extraction technology powered by AI.

35. argenx

Argenx is a global immunology company dedicated to improving the lives of people affected by severe autoimmune diseases. Through strategic partnerships with leading academic researchers, particularly under its Immunology Innovation Program (IIP), argenx works to translate cutting-edge immunology research into a portfolio of advanced antibody-based therapies.

The technology: Notably, argenx has developed and commercialized the first approved neonatal Fc receptor (FcRn) blocker across multiple regions, including the U.S., Japan, Israel, the EU, the UK, Canada, and China. The company is currently assessing its lead therapy, efgartigimod, across a range of serious autoimmune conditions, while simultaneously advancing a pipeline of early-stage experimental treatments within its therapeutic franchises.

Milestone: Headquartered in Boston, Massachusetts, with a team of 1,600 employees, argenx is also at the forefront of expanding treatment options for chronic inflammatory demyelinating polyneuropathy (CIDP). Recent milestones include the FDA approval of VYVGART Hytrulo for CIDP and the acceptance of its Supplemental Biologics License Application with priority review for the same condition.

36. Rightway

Rightway is the leader in driving healthcare value for everyone, everywhere. Its care navigation and PBM platforms guide over one million members to the highest-quality care and optimal therapies by inserting clinicians and pharmacists into the member care journey. Powerful technology enables one-on-one clinical guidance at a fraction of the cost of traditional care navigation solutions, reducing healthcare costs by 15%.

The technology: Its transparent PBM is the first to deliver fully aligned, pass-through pricing and personalized clinical management, transforming the member experience and lowering employer pharmacy spend by 15%.

The mission: Companies choose Rightway for its ability to reimagine the consumer experience, drive industry-leading engagement, and decrease healthcare costs.

37. Insilico Medicine

Insilico Medicine is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, that utilizes generative artificial intelligence to advance drug discovery and development. By integrating biology, chemistry, and clinical trial analysis through AI systems, Insilico Medicine is innovating within the pharmaceutical industry.

The technology: The company has developed proprietary AI platforms that employ deep generative models, reinforcement learning, transformers, and other machine learning techniques. These technologies enable novel target discovery and the generation of molecular structures with desired properties. Insilico Medicine focuses on developing therapies for various diseases, including cancer, fibrosis, immunity-related conditions, central nervous system disorders, infectious diseases, autoimmune diseases, and aging-related ailments.

Milestone: Recently, Insilico Medicine announced a collaboration with Inimmune, using its Chemistry42 platform to enhance the discovery and development of immunotherapeutics. Additionally, the company received IND approval and orphan drug designation from the FDA for ISM6331, an AI-designed TEAD inhibitor targeting solid tumors and mesothelioma. With a workforce of 300 employees, Insilico Medicine aims to impact the future of healthcare through its approach to drug development.

38. Kipu Health

Kipu is a leading enterprise software provider for the behavioral health industry, offering solutions in Electronic Medical Records (EMR), Customer Relationship Management (CRM), and Revenue Cycle Management (RCM). Its flagship product, KipuEMR, is the largest EMR specifically designed for the addiction treatment sector, used by over 80,000 users across more than 1,600 facilities worldwide. Kipu’s cloud-based platform manages the entire patient life cycle, from the first call to admission, treatment, follow-up, and billing.

The mission: Kipu focuses on efficiency to support patient-centered care. Its platform is tailored to the needs of addiction treatment and mental health professionals, helping reduce administrative burdens so providers can concentrate on patient care. This has enabled more than 1,600 facilities to enhance their clinical services and support individuals in recovery.

Kipu is committed to improving operational efficiencies and maximizing reimbursements for its clients. Recent acquisitions, such as Hatch Compliance, have strengthened its technology offerings with advanced compliance management solutions for behavioral health organizations.

Past Rankings from The Healthcare Technology Report:

The Top 25 Healthcare Software Companies of 2024 (No. 14)

39. Veradigm

Headquartered in Chicago, Illinois, Veradigm is a healthcare technology company that delivers value through a combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network includes a community of solutions and partners, offering insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets.

The technology: As an integrated data systems and services organization, Veradigm merges data-driven clinical insights with actionable tools to enhance the quality, efficiency, and value of healthcare delivery. Its stakeholders include biopharma companies, health plans, healthcare providers, network partners, and the patients they serve.

The mission: Veradigm’s team of about 1,500 employees focuses on empowering healthcare stakeholders to provide optimal care for healthier communities. The organization values diversity as essential to innovation and fosters an inclusive environment that supports the talents of all individuals.

40. Sutro Biopharma

Sutro Biopharma, a clinical-stage company headquartered in South San Francisco, is relentlessly focused on discovering and developing precisely designed cancer therapeutics, transforming what science can do for patients.

The technology: Sutro’s fit-for-purpose technology, including cell-free XpressCF, provides opportunities for broader patient benefit and an improved patient experience. The company has multiple clinical-stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, supported by high-value collaborations and industry partnerships, validates its continuous product innovation.

41. SS Innovations

SS Innovations International is a leading developer of surgical robotic technologies focused on making robotic surgery affordable and accessible to a wider global audience. The company’s flagship products include the proprietary “SSi Mantra” surgical robotic system and the “SSi Mudra,” a versatile range of surgical instruments designed for various procedures, including robotic cardiac surgery. Headquartered in India, SSII plans to expand its reach globally, providing user-friendly and cost-effective surgical solutions.

Founded by Dr. Sudhir Srivastava, a prominent robotic cardiac surgeon, SS Innovations International is transforming cardiothoracic surgery. As the Founder, Chairman, and CEO, Dr. Srivastava holds the record for the most robotic Beating Heart Totally Endoscopic Coronary Artery Bypass (TECAB) surgeries. His leadership has led to the development of the SSi Mantra system, which aims to decentralize excellence in surgical care and ensure advanced procedures are available to underserved populations worldwide.

Milestone: Recently, SS Innovations partnered with Medikabazaar, India’s leading medical equipment supplier, to enhance the sales of the SSi Mantra Surgical Robotic System to hospitals and medical facilities across India. This collaboration highlights SSII’s commitment to improving healthcare accessibility and advancing surgical innovation.

42. Promaxo

Promaxo, based in Oakland, California, is a medical technology company focused on transforming patient care through advanced imaging and robotic technologies.

The technology: Founded by healthcare innovators, Promaxo has developed a compact, patient-centric MRI and robotic-guidance system designed for in-office use, marking a new standard in accessibility and efficiency for real-time diagnosis and intervention. Backed by over 250 patents, the company received FDA 510(k) clearance for its MRI platform, enabling seamless prostate interventions with a single-sided scanner.

The mission: Promaxo is dedicated to making high-quality medical imaging more accessible, partnering strategically with investors and corporations to drive commercialization of its technology. By integrating AI, robotics, and state-of-the-art imaging, Promaxo aims to enhance patient outcomes and broaden access to precision healthcare.

Past Rankings from The Healthcare Technology Report:

The Top 100 Healthcare Technology Companies of 2021 (No. 40)

43. Caris Life Sciences

Caris Life Sciences is a leading next-generation AI techbio and precision medicine company focused on transforming healthcare and improving the human condition. Caris develops solutions that utilize comprehensive molecular profiling techniques, including Whole Exome and Whole Transcriptome Sequencing. By applying advanced artificial intelligence and machine learning algorithms, Caris has created a large-scale clinico-genomic database and computing infrastructure that enables the analysis of the molecular complexity of diseases.

The technology: The company’s integration of sequencing technology, big data, and AI establishes a robust platform for delivering precision medicine tools that support early detection, diagnosis, monitoring, therapy selection, and drug development.

The mission: Founded with the aim of realizing the potential of precision medicine, Caris values its employees and promotes diversity within its workforce, welcoming individuals of every creed, color, sex, sexual orientation, and religion.

Milestone: In November, the FDA approved Caris Life Sciences’s MI Cancer Seek as a companion diagnostic to multiple cancer drugs across six cancer indications.

44. Burlington Medical

Burlington Medical provides the highest quality, lightweight lead aprons in the industry. As experts in the health and safety concerns of radiation-exposed providers, it offers in-person fitting services, industry-leading lead times, and cost-saving options.

The mission: Its focus is on delivering superior protection while maximizing budget efficiency for all their customers.

45. Phathom Pharmaceuticals

Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases.

Showcase: Phathom has licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). Phathom currently markets VOQUEZNA (vonoprazan) tablets for the treatment of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and associated heartburn in adults, in addition to VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. In addition, the company is also advancing its development program across multiple acid-related GI disorders, including as-needed dosing for Non-Erosive GERD (NERD) and Eosinophilic Esophagitis (EoE).

The mission: Its focus is to transform the treatment landscape and improve the lives of patients suffering from acid-related GI disorders.

Past Rankings from The Healthcare Technology Report:

The Top 100 Healthcare Technology Companies of 2021 (No. 37)

46. Trusted Health

Trusted Health, based in San Francisco, California, is the leading labor marketplace for healthcare professionals revolutionizing travel nursing and empowering the nursing workforce. With a firm belief that clinicians deserve the very best tools and support available, Trusted Health has set out to mobilize the healthcare workforce by providing innovative technologies supporting overburdened clinicians and helping nurses build healthy, fulfilling careers. By allowing nurses to access all the necessary information and the right kind of support at their fingertips, Trusted Health is matching the right clinician to the right job, ultimately helping to ensure that the healthcare system functions better for everyone.

The technology: Trusted Health’s Works’ platform is an industry-pioneering workforce management solution helping hospitals drive clinical cost savings and bolster nurse retention through flexibility and workforce optimization. Works provides healthcare facilities with the software necessary to create their own on-demand nursing workforce and access one source of truth for all of their clinical workforce needs, from sourcing and onboarding to ongoing compliance.

Past Rankings from The Healthcare Technology Report:

Best HealthTech Companies to work for in San Francisco

47. Amwell

Amwell is a hybrid care delivery enablement platform based in the United States, focused on connecting and empowering providers, payers, patients, and innovators to improve access to affordable, high-quality healthcare. With nearly two decades of experience, Amwell believes in the potential of hybrid care delivery, offering a comprehensive platform that addresses various digital health needs, including urgent, acute, post-acute, chronic care, and healthy living.

The technology: The platform supports the digital care of over 50 health plans, collectively covering more than 100 million lives, and serves many of the nation’s largest health systems. Amwell’s approach extends beyond providing products; it fosters partnerships that connect stakeholders in the healthcare ecosystem, creating a continuum of care that encompasses in-person, virtual, and automated services.

The mission: At the core of Amwell’s mission is a commitment to empowering clients’ healthcare goals through a platform that integrates technologies, services, and devices to facilitate scalable care delivery anytime and anywhere. Supported by a team of experts and advanced technology, Amwell aims to achieve better outcomes for its clients.

48. BenchSci

As a global leader in enterprise AI solutions for drug discovery, BenchSci’s mission is to exponentially increase the speed and quality of life-saving R&D to help bring new medicines to patients faster. By harnessing the power of AI, BenchSci’s ASCEND platform is transforming preclinical research and development (R&D) within the pharmaceutical industry.

The technology: Today, ASCEND serves as an AI assistant for the brightest scientists at leading pharmaceutical companies. Its cutting-edge technology decodes and connects the vast landscape of biomedical research, multi-omics data, and integrates it with proprietary customer data. This creates an unbiased map of the underlying biology of disease, empowering scientists to discover novel insights and accelerate R&D. Its platform, ASCEND, increases the productivity of the preclinical R&D pipeline across therapeutic areas by supporting its core functions, from target ID and prioritization to experimental design and validation, all the way to translational workflows to ensure clinical success.

Milestone: Backed by top-tier investors, including Generation Investment Management (Al Gore’s firm), iNovia Capital, TCV, F-Prime, Gradient Ventures (Google’s AI fund), and Golden Ventures, BenchSci has raised over $200 million. Today, the platform accelerates science at 16 top 20 pharmaceutical companies and over 4,500 leading research centers worldwide.

49. Heidi Health

Heidi Health is the team behind the world’s most loved AI scribe, used daily by tens of thousands of clinicians in more than 50 countries, scribing millions of consults every month. Where other scribes end at transcription, Heidi is just getting started. Heidi’s real power is its ability to personalize notes with customized templates, create any healthcare document with a simple prompt, and enable seamless team collaboration through shared sessions for multi-disciplinary care and more.

The technology: From solo practitioners to large hospital networks, and in specialties ranging from primary care to neurology to OBGYN, Heidi adapts to unique workflows across all fields. Heidi is safe for every clinician to use, with HIPAA and NHS compliance fortified with SOC2 and ISO 27001 security. With 100 employees, Heidi Health is headquartered in Melbourne, Australia.

50. Elegen

The future of genetic medicine hinges on a reliable, streamlined DNA supply, a current development bottleneck—but Elegen is changing the game with its patented cell-free cloning technology. While conventional providers continue using outdated methods that limit length, complexity, and quality, Elegen achieves new levels of gene synthesis throughput, quality and efficiency, delivering DNA more reliably to fuel breakthroughs in R&D and clinical manufacturing.

The technology: Elegen’s ENFINIA® DNA is produced from a next-generation gene synthesis technology that reduces hands-on time by providing linear DNA that is 2x longer than conventional gene synthesis, with an NGS-verified accuracy 20x higher, and an industry-leading sequence complexity often rejected by other manufacturers. Unlike the decades-old gene synthesis technologies used by most providers, Elegen’s technology is cell-free from raw nucleotides to full-length linear double-stranded DNA. ENFINIA DNA’s length, complexity, accuracy and speed offers a turnkey supply of DNA to cost-effectively investigate a broader and more complex sequence space faster and accelerate clinical scaleup of DNA free of cell debris in the quest to bring advanced genetic medicine to patients faster.

Milestone: Earlier this year, Elegen and GSK announced a multi-year collaboration and licensing agreement to use Elegen’s cell-free DNA manufacturing technology in the development of GSK’s medicines and vaccines, including mRNA vaccines.

Past Rankings from The Healthcare Technology Report:

The Top 25 Biotechnology Companies of 2024 (No. 17)

51. Natus Medical

Natus Medical is a provider of medical equipment, software, supplies, and services for the diagnosis, monitoring, and treatment of disorders affecting the brain, neural pathways, and sensory nervous systems. Trusted by healthcare providers worldwide, Natus offers a comprehensive product portfolio that reflects over 80 years of innovation in patient care.

The technology: The company’s solutions, which include service, field support, and education, enable clinicians to improve their standard of care, resulting in better patient outcomes and quality of life. Natus products are used in university medical centers, hospitals, private practices, clinics, and research laboratories.

The mission: Headquartered in Middleton, Wisconsin, Natus employs approximately 1,100 professionals who are committed to fostering an inclusive and respectful workplace.

Milestone: Natus Medical appointed Chris Landon as its new CEO in 2024.

52. Angle Health

Angle Health is a startup health plan and healthcare technology company providing a modern, digital-first approach to healthcare benefits. Serving as a one-stop healthcare benefits solution for employers, Angle Health offers fully custom, full service health plans to employers, with a personalized healthcare experience for members.

The technology: Angle Health’s AI-enabled full-stack healthcare platform automates processes and streamlines administration—from instant quoting to real-time enrollment and ID cards to claims processing to a concierge care team—to deliver a seamless experience across brokers, employers, members, and providers.

The mission: Angle Health is building a new vision of the healthcare system and on a mission to bring transparency, simplicity, and humanity back to healthcare so people can live their best lives.

53. Microbiologics

Microbiologics is a leading provider of biological products and services, focused on protecting global health and safety. With over 50 years of expertise, Microbiologics partners with healthcare and life science laboratories, manufacturers, and suppliers worldwide to deliver biological control materials, assay services, and consulting solutions across microbiology, molecular diagnostics, and virology.

The mission: Headquartered in Saint Cloud, Minnesota, with additional facilities in California, Kentucky, and Michigan, Microbiologics upholds rigorous testing and quality standards. The company’s distribution network, spanning over 150 countries, reflects its commitment to advancing industry standards and ensuring accessible biological solutions globally.

Milestone: In November, Microbiologics acquired German company SensID, a manufacturer of reference materials and quality controls for molecular diagnostics. SensID specializes in providing intensely characterized reference materials and quality controls used for R&D, validation, and quality control of molecular diagnostic tests.

54. CodaMetrix

Founded in 2019, CodaMetrix is made up of healthcare, technology, revenue cycle management, and data science experts.

The technology: Its multi-specialty autonomous medical coding platform leverages AI to continuously learn from and act upon the clinical evidence in the EHR. It autonomously translates clinical notes into billing codes that satisfy coding requirements, ensuring claims consistently represent the unique and complete episode of care, reducing human coding and provider workload while improving the efficiency and optimizing the quality of medical coding.

Past Rankings from The Healthcare Technology Report:

Best HealthTech Companies to work for in Boston

55. PTC Therapeutics

PTC Therapeutics is a global biopharmaceutical company focused on discovering, developing, and commercializing clinically differentiated medicines for children and adults with rare disorders.

The mission: The company is dedicated to innovation, enabling it to identify new therapies and effectively bring products to market, resulting in a strong and diverse pipeline of transformative medicines. PTC’s mission is to provide access to best-in-class treatments for patients with limited or no options.

Milestone: Recently, PTC Therapeutics made significant strides with the U.S. Food and Drug Administration’s (FDA) acceptance of the resubmission of the New Drug Application (NDA) for Translarna (ataluren), aimed at treating nonsense mutation Duchenne muscular dystrophy (nmDMD). The FDA also accepted the filing of the Biologics License Application (BLA) for Upstaza (eladocagene exuparvovec), a gene therapy for AADC deficiency, and the NDA for Sepiapterin, designed for pediatric and adult patients with phenylketonuria. These milestones highlight PTC’s commitment to advancing healthcare solutions for rare disorders.

Past Rankings from The Healthcare Technology Report:

The Top 100 Healthcare Technology Companies of 2023 (No. 34)

56. Livara Health

Livara Health is a value-based musculoskeletal management solution for innovative providers, payors and value-based health systems which works with patients to build their body’s potential to recover from acute or chronic pain. Guided by 18 years of direct patient care, Livara identifies and engages at-risk patients to enroll in our program. Leveraging a multidisciplinary team including surgeons, athletic trainers, licensed clinical social workers and nutritionists, Livara guides patients through a tailored plan of care to reduce their pain and improve their function. When necessary, Livara may navigate patients to a curated and high performing network of in person care.

The technology: Compared to traditional conservative treatment options or digital solutions that are limited in their scope, Livara optimizes the pathways for everyone in a population from the preventative to the acute and pre-surgical. With several multi-year claims based studies proving our impact on outcomes and cost of care, Livara partners with commercial and Medicare payors and providers through flexible value-based payment arrangements, including assuming total cost of MSK care.

57. SAB BIO

SAB BIO (SAB) is a clinical-stage biopharmaceutical company focused on developing human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders.

The technology: The Company’s lead asset, SAB-142, targets T1D with a disease-modifying therapeutic approach that aims to change the treatment paradigm by delaying onset and potentially preventing disease progression. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, SAB’s DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, human IgGs that can address a wide range of serious unmet needs in human diseases without the need for convalescent plasma or human donors.

58. Nym

Nym is focused on transforming clinical language into actionable information, addressing inefficiencies that contribute billions to healthcare costs. By leveraging advanced technology alongside clinical expertise and a strong understanding of medical language, Nym accurately decodes medical charts in a manner that is efficient and compliant.

The technology: The company’s revenue cycle management (RCM) solution automates the translation of provider notes within patient charts into precise diagnostic and billing charge codes, completing this task within seconds and without human intervention. With over 95% accuracy in improved coding, Nym’s RCM solution provides audit-ready, traceable documentation for each code generated, ensuring transparency regarding the rationale behind every assignment. This scalable solution adapts to varying volumes and workflow needs, reducing administrative burdens and allowing clinical teams to concentrate more on patient care.

Partner spotlight: Headquartered in New York City, Nym also has research and development capabilities in Tel Aviv. The company is building an interdisciplinary team of specialists, including technologists, physicians, mathematicians, computational linguists, engineers, and medical coders. Nym’s growth has attracted investors such as PSG, Addition, GV, Bessemer Venture Partners, Dynamic Loop Capital, Tiger Global, Zach Weinberg, and Nat Turner.

Past Rankings from The Healthcare Technology Report:

The Top 25 Healthcare Software Companies of 2024 (No. 15)

59. Axxess

Axxess is a leading global technology platform dedicated to transforming healthcare at home. Headquartered in Dallas, Texas, the company boasts a workforce of 1,000 employees and is recognized for its innovative approach to solving complex industry challenges. Axxess provides a robust ecosystem that empowers healthcare organizations and professionals to deliver high-quality care to patients in their homes.

The mission: Trusted by over 9,000 organizations, Axxess supports the care of more than 5 million patients worldwide. The company offers a comprehensive suite of user-friendly software solutions tailored for home health, home care, hospice, and palliative providers, aiming to make healthcare in the home more humane and effective. Axxess’s commitment to security and compliance is underscored by multiple independent certifications, validating that it offers the most secure and industry-compliant software solutions available to providers in the healthcare sector.

60. Kontakt.io

Kontakt.io stands at the forefront of Indoor Journey Analytics, revolutionizing how businesses understand and optimize customer movement within their spaces. Leveraging cutting-edge technologies such as Real-Time Location Systems (RTLS), the Internet of Things (IoT), and Artificial Intelligence (AI), Kontakt.io provides invaluable insights that help organizations uncover inefficiencies, streamline operations, and enhance the experience for both customers and staff.

Since its inception in 2013, Kontakt.io has made significant strides in the industry, delivering innovative solutions to over 32,000 end users through a robust network of more than 1,200 partners. The company has deployed over 4 million IoT devices globally, demonstrating its capacity for impactful, large-scale implementation.

Milestone: Recently, Kontakt.io has expanded its offerings with the launch of a new Hand Hygiene Solution, aimed at enhancing compliance and staff engagement in hospitals. The company also received funding from Goldman Sachs to accelerate its AI development and broaden its reach into U.S. healthcare facilities.

Past Rankings from The Healthcare Technology Report:

The Top 25 Healthcare Software Companies of 2024 (No. 18)

The Top 100 Healthcare Technology Companies of 2023 (No. 66)

61. Simple App

Simple supports weight loss through seamless meal logging and flexible intermittent fasting tracking, coupled with a unique, award-winning Nutrition Score that focuses on balanced eating without the need to count calories or weigh food. With personalized food feedback, meal plans, and workout recommendations, users are empowered to follow a holistic plan designed to support their weight loss journey.

Simple is a mobile application with over 17 million downloads from across the world and a team spanning 32 countries. Simple empowers people to become their healthiest, most energized and confident selves every day through easy-to-follow, effective, and personalized weight loss programs delivered through a smart coach that helps people to take sustainable steps towards weight loss, and ultimately supporting their long-term health.

The technology: The journey is guided by Avo, the cutting-edge AI coach, offering personalized daily plans, motivational check-ins, and proactive coaching. Avo’s support adapts to each user’s progress, providing the support they need to achieve sustainable weight loss and better health.

62. Abcuro

Abcuro, Inc. is a privately held, late clinical stage, biotechnology company working to deliver first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T and NK cells.

Showcase: The Newton, Massachusetts based company, through its grounding in strength and laser focus on bettering the lives of patients with T cell driven autoimmune disease, has been diligently working to progress its lead investigational candidate ulviprubart (ABC008), a first-in-class anti-KLRG1 antibody, forward. Currently in clinical trials for the treatment of Inclusion Body Myositis (IBM) and T Cell Large Granular Lymphocytic Leukemia (T-LGLL), ulviprubart has been designed to selectively deplete highly cytotoxic T cells, while sparing naïve, regulatory and central memory T cells, which are believed to possibly stabilize the immune system and address the underlying cause of the disease.

The mission: The Company’s dedication to those living with IBM, a relentlessly progressive muscle disease in which patients lose their ability to walk, use their hands and often do not swallow effectively, is evident. While staying steadfast in its science, Abcuro has constantly made its focus on patients a guiding light, partnering with advocacy organizations Myositis Support and Understanding and The Myositis Association for whom it serves on the corporate advisory council.

Milestone: Steered by strong leadership and a team dedicated to delivering potential treatment to patients currently living without options, Abcuro raised $155 million in a Series B financing in 2023, bringing the company to around $245 million raised overall. These funds help to drive its ongoing Phase 1 and Phase 2/3 studies of ulviprubart in IBM and Phase 1/2 study of ulviprubart in T-LGLL and allow Abcuro to continue leading the way in cytoxic T cell depletion to address T cell-driven autoimmune disease.

63. Maven Clinic

Maven is a virtual clinic focused on women’s and family health, providing comprehensive care worldwide. Founded in 2014 by CEO Kate Ryder, the Maven team includes clinical leaders, engineers, designers, and operators who work together to offer localized support to members in 175 countries.

The technology: Maven’s digital programs facilitate ongoing care in fertility, family building, maternity, parenting, pediatrics, and menopause. The clinic is recognized for its role in reducing costs and improving maternal health outcomes, as well as promoting diversity, equity, and inclusion in benefits programs.

Partner spotlight: With 15 million lives covered and $300 million in funding from investors such as General Catalyst, Sequoia, Oak HC/FT, Dragoneer Investment Group, and Lux Capital, Maven is recognized as a leader in the healthcare sector.

Past Rankings from The Healthcare Technology Report:

The Top 100 Healthcare Technology Companies of 2023 (No. 43)

64. Arcturus Therapeutics

Arcturus Therapeutics Holdings, a San Diego-based company founded in 2013, is a global developer of mRNA medicines and vaccines.

The technology: Known for its proprietary LUNAR® lipid-mediated delivery and STARR® mRNA technologies, Arcturus introduced the world’s first approved self-amplifying mRNA (sa-mRNA) COVID-19 vaccine. In addition to its work in mRNA vaccine technology, Arcturus collaborates with CSL Seqirus on mRNA vaccine development and operates ARCALIS, a joint venture in Japan focused on mRNA vaccine and therapeutic manufacturing.

Arcturus’ pipeline addresses significant medical needs, including RNA-based treatments for rare conditions such as ornithine transcarbamylase deficiency and cystic fibrosis, as well as mRNA vaccines for COVID-19 and influenza. Its platforms extend across a range of nucleic acid therapeutics, including siRNA, antisense RNA, circular RNA, DNA, and gene editing, supported by over 400 patents worldwide. Recently, the company received Orphan Medicinal Product Designation from the European Commission for ARCT-032, targeting cystic fibrosis.

Past Rankings from The Healthcare Technology Report:

The Top 25 Biotechnology Companies of 2024 (No. 12)

65. Welldoc

The Welldoc digital health platform integrates personalized, real-time and actionable insights into the daily lives of individuals with cardiometabolic conditions, enabling improved health and outcomes. Welldoc’s AI-powered platform delivers a total health approach with flexible, multi-condition digital coaching across diabetes, hypertension, heart failure, weight management with GLP-1 support, and prediabetes, with integrated mental wellbeing and sleep support.

The technology: The Welldoc platform brings first-in-class, evidence based clinical, tech, and advanced AI expertise, as demonstrated by the company’s 80+ clinical posters and publications, 45 patents, and 11 510(k) FDA clearances for diabetes functionality. Welldoc enables health plans, health systems and employers to extend care beyond traditional models, and partners with pharma and med device industry leaders to develop first-in-class, regulated combination products.

Welldoc continues to lead the charge in AI capabilities, making more personalized insights and feedback a reality in healthcare. To date, the company has published 37 peer-reviewed AI clinical publications, built a robust data intelligence platform, and established a sophisticated AI approach that balances intent with risk to assess appropriate regulatory and clinical pathways.

The mission: In a landscape consumed by excessive, invalidated AI claims, Welldoc is taking a systematic approach to AI and setting a higher standard for the entire digital health industry.

Past Rankings from The Healthcare Technology Report:

The Top 100 Healthcare Technology Companies of 2023 (No. 49)

66. Ostro

Ostro was founded to help millions of people live healthier lives by creating personalized healthcare journeys that drive the next best actions for consumers and HCPs, while delivering value for life sciences brands. Its AI-powered digital engagement solution supports HCP, consumer, and data applications, partnering with life science brands across therapeutic areas like oncology, rare diseases, and dermatology.

The mission: Ostro’s team of experts is composed of engineers, product innovators, designers from Google, Amazon, McKinsey, Hims & Hers, as well as regulatory experts and doctors, all focused on delivering next-generation life science software solutions. Ostro is not just a company. It’s a movement for better communication and engagement in healthcare, and a commitment to a future where everyone has the tools they need to make informed decisions about their health

67. Sword Health

Sword Health is a leader in AI-based care, integrating human clinicians with artificial intelligence to improve access to healthcare. The company addresses various health issues, starting with physical pain and expanding to pelvic health. Sword Health partners with over 3,000 employers, health plans, and public sector organizations, helping clients save an average of $3 in healthcare costs for every dollar invested.

The mission: The company aims to free two billion people from pain and has raised over $300 million from venture capital firms, including Khosla Ventures, General Catalyst, and Founders Fund, reaching a valuation of $3 billion.

68. Scientist.com

Scientist.com is a privately held, San Diego-based company on a mission to empower and connect scientists and make it faster and cheaper to discover new medicines. At its heart is an AI-powered marketplace for complex research experiments with the potential to transform the pharmaceutical industry in the same way Amazon has transformed the retail industry. Scientist.com’s clients include most of the world’s largest pharmaceutical companies, 100+ biotechs and the U.S. National Institutes of Health. Through Scientist.com, these clients communicate directly with research experts at over 5,000 global laboratories to design and execute complex research experiments.

Past Rankings from The Healthcare Technology Report:

The Top 25 Biotechnology Companies of 2024 (No. 14)

The Top 100 Healthcare Technology Companies of 2023 (No. 53)

69. Orca Bio

Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of blood cancer and autoimmune diseases. Headquartered in Menlo Park, California, with a state-of-the-art cGMP manufacturing facility in Sacramento, California, Orca Bio’s platform uses single-cell precision to create proprietary, uniquely-defined allogeneic T-cell immunotherapies designed to fully replace patients’ diseased blood and immune system with healthy ones. Its team of leading scientists, engineers, clinicians and industry professionals are committed to developing treatments for patients with the goal of providing better outcomes with fewer risks than the standard of care.

Milestone: Orca Bio recently completed enrollment of Precision-T, a pivotal Phase 3 clinical trial evaluating its lead investigational product, Orca-T, for the treatment of blood cancers and other hematological malignancies. In parallel, the company is advancing next-generation programs to expand its pipeline and bring the promise of cell therapies to all patients who could potentially benefit.

The mission: Orca Bio’s mission is to make curative cell therapies both safer and more effective, and in doing so, push past the field’s current boundaries and redefine its future.

70. Bamboo Health

Bamboo Health, headquartered in Louisville, Kentucky, empowers healthcare organizations to improve behavioral and physical health outcomes through its Real-Time Care Intelligence platform, which facilitates a care collaboration network. By delivering real-time insights during critical care moments, Bamboo Health enables its clients to take effective actions, ensuring the provision of high-quality and cost-effective whole-person healthcare.

Partner spotlight: With a broad reach across the United States, Bamboo Health partners with all major retail pharmacy chains and operates in all 52 states and territories. It collaborates with 100% of the top 10 hospitals and more than half of the country’s largest health plans, collectively improving over one billion patient encounters annually. This extensive network positions Bamboo Health as a key player in transforming healthcare delivery nationwide.

71. Omada Health

Omada Health is a leading virtual-first healthcare provider focused on promoting lifelong health through innovative, evidence-based interventions. Its care teams use clinically validated behavior change protocols to assist individuals managing chronic conditions like diabetes, hypertension, prediabetes, weight management, and musculoskeletal issues.

The mission: With over a decade of experience and 29 peer-reviewed publications demonstrating their clinical and economic impact, Omada is committed to improving health outcomes while controlling healthcare costs.

The technology: As the first virtual provider to join the Institute for Healthcare Improvement’s Leadership Alliance, Omada enhances primary care by integrating clinical insights with technology, amplifying the effectiveness of its care teams, including health coaches and clinical specialists.

Milestone: Recently, Omada partnered with the State of Alaska to serve rural populations through the Fresh Start Campaign, providing thousands of residents access to virtual prevention, diabetes, and hypertension coaching programs. With nearly one million members enrolled across all 50 states, Omada Health is setting a new standard in virtual healthcare delivery.

Past Rankings from The Healthcare Technology Report:

The Top 25 Consumer Healthtech Companies of 2024 (No. 9)

The Top 100 Healthcare Technology Companies of 2022 (No. 55)

72. Relias

Relias is a leading provider of lifelong workforce enablement solutions, serving over 12,000 healthcare and human services organizations and supporting 4.5 million caregivers. The company is dedicated to driving measurable outcomes through its comprehensive suite of technology, services, community engagement, and expertise. Relias aims to attract and retain talent, elevate care quality, and reduce risks, ultimately improving the lives of the most vulnerable members of society and those who care for them.

The mission: The Relias family of brands, which includes Nurse.com, Wound Care Education Institute, Relias Academy, FreeCME, and Relias Media, serves the entire healthcare community with a shared commitment to enhancing clinical and financial outcomes. By focusing on reducing variation in care, Relias helps its clients deliver better results. Their platform utilizes performance metrics and assessments to identify specific gaps in clinical knowledge, addressing these gaps with personalized and engaging learning experiences.

With a workforce of around 1,000 employees and headquartered in Morrisville, North Carolina, Relias recently launched a Free Emergency Preparedness Hub to support healthcare professionals and organizations during disasters. Through its innovative solutions and dedication to continuous improvement, Relias is committed to helping healthcare organizations, their staff, and the individuals under their care get better at identifying issues, addressing them, and achieving improved outcomes for all.

Past Rankings from The Healthcare Technology Report:

The Top 25 Healthcare Software Companies of 2024 (No. 8)

The Top 100 Healthcare Technology Companies of 2023 (No. 10)

The Top 100 Healthcare Technology Companies of 2022 (No. 92)

73. Cynerio

Cynerio’s Healthcare Cybersecurity Platform is tailored to safeguard medical environments against constantly evolving threats. From real-time detection of malicious network activity to strategic microsegmentation guidance, Cynerio delivers a robust suite of proactive and reactive protections that elevate the security of healthcare facilities and ensure the safety of the patients they serve.

Past Rankings from The Healthcare Technology Report:

The Top 100 Healthcare Technology Companies of 2022 (No. 86)

74. KLOwen Orthodontics

KLOwen Orthodontics is a custom digital technology company transforming orthodontic practices through its full custom digital orthodontic solution that increases efficiency, improves quality and consistency of outcomes, and reduces stress in the orthodontic practice. Founded in 2019 by orthodontist Dr. Brandon Owen, KLOwen is leading innovation in orthodontic treatment with a full portfolio of custom fixed appliances proven to deliver an average of 7.1 fewer appointments per patient.

75. Iovance Biotherapeutics

Iovance Biotherapeutics aims to be a leader in the innovation, development, and delivery of tumor infiltrating lymphocyte (TIL) therapies for cancer patients. The company is focused on a new approach to cancer treatment by utilizing the human immune system’s ability to recognize and eliminate a variety of cancer cells specific to each patient. The Iovance TIL platform has demonstrated positive clinical results across multiple solid tumors, highlighting the potential of their therapies.

The mission: Iovance is committed to continuous innovation in cell therapy and is exploring gene-edited cell therapies that may offer additional treatment options for cancer patients. As the company prepares for its commercial launch, it is expanding its team, advancing research and development efforts, and enhancing internal manufacturing capabilities.

Iovance is headquartered in the San Francisco Bay Area, with its Iovance Cell Therapy Center (iCTC) located in Philadelphia. The company also has a research site in Tampa, Florida, reinforcing its mission to transform cancer treatment through effective cell therapies.

Past Rankings from The Healthcare Technology Report:

The Top 25 Biotechnology Companies of 2024 (No. 15)

76. OrthAlign

OrthAlign, a medical device company, develops practical, advanced technologies for orthopedic surgery, focusing on accessible and clinically proven joint replacement solutions. OrthAlign equips surgeons with tools that enhance patient care in a cost-effective, user-friendly package. Using micro-electromechanical sensors, OrthAlign’s live-navigation technology supports partial knee, total knee, and total hip replacements across multiple surgical approaches, ensuring accuracy and ease of integration.

Milestone: With FDA 510(k) clearance for its Lantern® Hip handheld technology for direct anterior total hip arthroplasty, OrthAlign continues to expand its impact, launching Lantern® for knee arthroplasty in Japan. OrthAlign is dedicated to making high-quality healthcare technology accessible and affordable worldwide.

77. DermaSensor

DermaSensor Inc. is a health technology company designing non-invasive tools to better equip all physicians for skin cancer detection. The DermaSensor device is an affordable, handheld tool that uses spectroscopy and algorithms to test skin lesions for cancer in seconds. It is currently FDA Cleared, CE Marked, and is available for sale in the U.S.

78. PartsSource

PartsSource is a pioneering company founded on the principle that an evidence-based, digital approach to the healthcare supply chain can significantly enhance delivery, reduce costs, and improve clinical outcomes. Today, it stands as the largest online marketplace in U.S. healthcare, actively transforming one of the world’s largest industries.

The technology: As a leading evidence-based B2B vertical marketplace and supply chain software platform, PartsSource serves the healthcare provider and supplier ecosystem. It is dedicated to enhancing essential clinical operations, boosting staff productivity, controlling costs, maximizing asset uptime, and strengthening supply chain resiliency. Currently, PartsSource supports over 5,000 member hospitals and more than 15,000 clinical sites, helping them achieve sustainable savings and operational efficiencies.

The mission: Recognized as healthcare’s premier source of knowledge, processes, and components, PartsSource is committed to revolutionizing supply chains and workflows. The company’s solutions not only automate the complex procurement and vendor management processes but also identify new opportunities for efficiencies and improved service availability. With a workforce of 500 employees, PartsSource is headquartered in Cleveland, Ohio, ensuring that healthcare services remain consistently accessible.

Past Rankings from The Healthcare Technology Report:

The Top 25 Healthcare Software Companies of 2024 (No. 11)

The Top 100 Healthcare Technology Companies of 2023 (No. 37)

The Top 100 Healthcare Technology Companies of 2021 (No. 18)

79. Viz.ai

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700+ hospitals and health systems in the U.S. and Europe.

The technology: The AI-powered Viz.ai OneTM is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies.

Past Rankings from The Healthcare Technology Report:

The Top 25 Healthcare Software Companies of 2024 (No. 23)

The Top 100 Healthcare Technology Companies of 2023 (No. 41)

Best HealthTech Companies to work for in San Francisco

80. Outset Medical

Outset Medical is a leading medical technology company focused on transforming the dialysis experience through innovative solutions. Its flagship product, Tablo, serves as a comprehensive enterprise solution, enabling dialysis to be delivered anytime and anywhere. Its design includes water purification and on-demand dialysate production, enabling portability. The system also features two-way wireless data transmission and a proprietary data analytics platform, enhancing patient care and operational efficiency.

Milestone: The company’s flagship product, the Tablo Hemodialysis System, has received FDA clearance for use in various settings, from hospitals to home care. This advanced technology reduces the cost and complexity of dialysis, making it more accessible for patients and providers.

Past Rankings from The Healthcare Technology Report:

The Top 100 Healthcare Technology Companies of 2023 (No. 54)

81. Visualutions

Visualutions is a healthcare technology company and revenue cycle solutions partner dedicated to providing clinical, financial, and IT solutions for enterprise organizations such as Federally Qualified Health Centers (FQHC), Rural Health Centers, Indian Health Services (IHS), Public Health Departments, and Freestanding Emergency Rooms. With over two decades of experience, Visualutions has built a diverse portfolio of products and services designed to address the complex challenges facing community health organizations across the nation.

The mission: Driven by a commitment to mission-driven healthcare, Visualutions prioritizes the needs of the communities it serves, working with partners who are passionate about supporting underserved populations. The company’s solutions optimize revenue cycles, enhance productivity workflows, and offer value-added services that empower healthcare organizations to deliver quality care. Visualutions also prioritizes maintaining power, security, and HIPAA compliance, ensuring that clients’ IT systems run seamlessly and securely.

Visualutions’ approach reflects corporate responsibility through its focus on sustainability, social impact, and alignment with global goals. As a strategic IT partner, Visualutions is dedicated to empowering community health providers to achieve their patient-centered missions, improving access to medical, dental, vision, and behavioral health services across the country.

82. Forward Advantage

Forward Advantage, based in Fresno, California, is a dynamic technology company dedicated to delivering innovative solutions for the healthcare industry. With a strong emphasis on secure access to information and efficient workflows, the company goes beyond merely selling products; it prioritizes building lasting relationships with its customers.

The mission: At Forward Advantage, teamwork is at the heart of its operations. The company’s employees share a passion for serving customers, whether it involves tackling complex support issues, designing new products, or collaborating with technology vendors. By consistently placing the success of their customers and partners at the forefront of the mission, Forward Advantage has established itself as a trusted ally in the healthcare technology landscape.

The company empowers clinicians to do their jobs as efficiently and effectively as possible so they can focus on patient care. Its suite of data-driving solutions enhances any HCIS and has been doing so since 1993. Known for its strong customer service, the company focuses on adding value to existing systems.

83. Codonics

Codonics, Inc. is a globally recognized leader in healthcare technology, committed to advancing patient safety and clinical efficiency. With a strong foundation in innovation, Codonics designs and manufactures cutting-edge medical devices, including its award-winning Safe Label System® (SLS), which has revolutionized the way hospitals approach medication preparation and administration by integrating barcode scanning, visual and audible safety checks, and on-demand full-color medication label output. This technology creates a standardization for the perioperative area and ensures compliance with The Joint Commission (TJC) requirements, American Society of Anesthesiologists (ASA) guidelines, recommendations from the Institute for Safe Medication Practices (ISMP), and dramatically reduces medication errors anywhere medications are prepared.

Codonics solutions are used in over 15,500 operating rooms and trusted in more than 1,000 hospitals worldwide, from small clinics to world-renowned healthcare facilities. The system seamlessly integrates with electronic health record (EHR) systems, including Epic and Cerner, improving documentation accuracy, patient safety and the anesthesia workflow. At the same time, SLS improves charge capture to deliver an ROI to the hospital.

The technology: The SLS 600i is next-generation innovation with advanced capabilities and an upgrade path for RFID integration “future-proofing” hospitals as demand grows for RFID-tagged products in healthcare. This advancement paves the way for enhanced track-and-trace functionality, giving hospitals a powerful tool to better manage medication safety and inventory control.

The mission: With a robust portfolio of patented technologies in areas such as image documentation, medication safety, and perioperative management, Codonics has set new best practice standards in healthcare. Driven by a commitment to innovation, patient safety, and regulatory compliance, Codonics continues to shape the future of healthcare technology, helping clinicians deliver safer, more efficient care.

84. Intellia Therapeutics

Intellia Therapeutics is a clinical-stage gene editing company focused on transforming medicine with CRISPR-based therapies. It develops innovative treatments using both in vivo and ex vivo programs. In vivo programs utilize CRISPR technology to edit disease-causing genes directly within the human body, while ex vivo programs engineer human cells outside the body to treat cancers and autoimmune diseases. Co-Founder Jennifer Doudna was awarded the 2020 Nobel Prize in Chemistry for her pioneering work in CRISPR, reinforcing the company’s leadership in this field.

The technology: Driven by a commitment to patients, Intellia’s researchers leverage CRISPR technology for therapeutic applications. The CRISPR/Cas9 system is central to Intellia’s mission, as it offers the potential to permanently edit disease-associated genes with a single treatment. This technology provides new hope for patients with limited options. With strong scientific expertise, clinical development experience, and a robust intellectual property portfolio, Intellia is poised to unlock the broad therapeutic applications of CRISPR/Cas9 technology and advance curative products into the clinic, ultimately aiming to deliver transformative solutions to patients in need.

85. CliniComp

CliniComp is a pioneering healthcare technology company with over four decades of experience in delivering cutting-edge electronic health record (EHR) solutions.

The technology: The company’s innovative System as a Service (SYaaS) model revolutionizes the EHR landscape by offering a comprehensive, all-inclusive solution suite that bundles software, hardware, and ongoing services at a fixed price. This approach dramatically lowers the total cost of ownership for healthcare organizations while providing rapid implementation, unparalleled reliability, and reduced IT burden. CliniComp’s architectural framework conquers evolving challenges with interoperability, scalability, and real-time performance data, enabling a truly comprehensive longitudinal patient record that seamlessly crosses multiple sites and env

Leading the way with the power of innovation

Athletech News is proud to present The Most Innovative Fitness & Wellness Companies of 2023. As the world’s only award dedicated to recognizing the pioneering achievements of brands in this fast-growing industry, this list serves as the ultimate authority in recognizing the organizations that are revolutionizing fitness and wellness and, by extension, positively influencing society.

From VR fitness to cutting-edge recovery tools to artificial intelligence, fitness and wellness companies are working on some truly amazing products and services, and it’s clear they’re just getting started.

An esteemed panel of outside judges, along with ATN’s founder and executive editor, spent many hours analyzing, debating and ultimately selecting the winning companies from a pool of many deserving applicants. It’s been our privilege, honor and duty to select the 23 companies we collectively feel are most deserving of a spot in the ATN 23, along with a select group of honorable mentions, our “Ones To Watch.”

We’d like to sincerely thank everyone who applied to the ATN 23, making our jobs as judges very difficult but highly rewarding. We hope you enjoy learning more about the Most Innovative Companies in Fitness & Wellness.